FYN and VEGFR2 kinase inhibitors
By developing N-phenylcarbamoyl compounds that selectively inhibit VEGF receptor VEGFR-2 and Fyn kinase, the systemic toxicity problem of existing technologies that are difficult to effectively treat diseases such as osteoarthritis has been solved, and highly effective therapeutic effects have been achieved through local application.
Patent Information
- Application Number
- CN202080095986.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-09
- Filing Date
- 2020-12-07
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-12-07
AI Technical Summary
Existing technologies are unable to effectively inhibit VEGF receptor VEGFR-2 and Fyn kinase, making it difficult to control pain and inflammation in diseases such as osteoarthritis, and traditional drugs may cause systemic toxicity problems.
A class of N-phenylcarbamoyl compounds has been developed that can selectively inhibit VEGF receptor VEGFR-2 and Fyn kinase, reduce systemic concentration through local application, reduce systemic toxicity, and provide therapeutic effects for diseases such as osteoarthritis.
When applied topically, this compound effectively inhibits VEGFR-2 and Fyn kinases, reduces systemic toxicity, and offers therapeutic potential for diseases such as osteoarthritis, particularly for the relief of acute and chronic pain. It is also applicable to a variety of diseases, including eye diseases, skin diseases, lung diseases, and certain cancers.
Smart Images

Figure CN115279747B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to N-phenylcarbamoyl compounds of formula (I) as FYN and VEGFR2 kinase inhibitors. Background Art
[0002] Protein kinases are promising drug targets for the treatment of a variety of conditions such as cancer, autoimmune diseases, inflammation or neurodegenerative diseases. Fyn is an intracellular tyrosine kinase in the Src family of kinases (SFKs) and is involved in a variety of biological processes (e.g., growth factor and cytokine receptor signaling, T cell and B cell receptor signaling, ion channel function, platelet activation and natural killer cell differentiation). Many literature data indicate that Fyn plays a major role in mediating pain. NMDA receptor phosphorylation is essential for the maintenance of neuropathic pain and is primarily dependent on Fyn activation. This role of Fyn was further deepened by the fact that Fyn-dependent phosphorylation of NMDA and AMPA is also closely related to experimental models of inflammatory pain and is essential for the development of tactile allodynia in the prediabetic neuropathy state of mice.
[0003] A recent study showed that among the SFK family, only Fyn is the most strongly upregulated protein in degenerated and damaged articular cartilage of aged mice. In addition, Fyn levels are elevated in experimental OA mouse cartilage and human OA cartilage from subjects undergoing total knee replacement. (Li, K. et al. Tyrosine kinase Fyn promotes osteoarthritis by activating the β-catenin pathway. Ann. Rheum. Dis. annrheumdis-2017-212658, 2018).
[0004] In the late stage of OA in affected patients, increased expression of vascular endothelial growth factor (VEGF), a potent angiogenic factor, was found in articular cartilage, synovium, synovial fluid, subchondral bone, and serum. Evaluation of VEGF as a biomarker in OA patients showed that increased synovial fluid VEGF correlated not only with OA severity grade but also with OA pain severity. VEGF signaling is mediated by three kinase insert domain receptors (receptor tyrosine kinases or RTKs), VEGFR-1, VEGFR-2, and VEGFR-3, with VEGFA / VEGFR2 being the most dominant ligand-receptor complex in the VEGF system and playing a key role in angiogenesis. In endothelial cells, VEGF / VEGFR2 binding causes Fyn activation, which in turn triggers a series of downstream signaling pathways, resulting in actin polymerization, stress fiber formation, and endothelial cell migration, which are essential for promoting the growth of new blood vessels. (Lamalice et al, Phosphorylation of Tyr1214 within VEGFR-2Triggers the Recruitment of Nck and Activation of Fyn Leading to SAPK2 / p38 Activation and EndothelialCell Migration in Response to VEGF, 281, 34009-34020, 2006).
[0005] In addition, a large number of studies have found that VEGF signaling in chondrocytes affects pro-catabolic mediators (i.e., matrix metalloproteinases, proteoglycanases), and the dual effects of VEGF and inflammatory cytokines on chondrocytes may exacerbate cartilage degeneration. Inflammatory pathways are associated with the progression of OA, angiogenesis stimulates inflammation, and inflammation promotes angiogenesis. (Hamilton, J. Let al. Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. J. Bone Miner. Res. 31, 911–924 (2016)). In addition, inflammation is a classic mediator of sensitization of thin unmyelinated sensory nerves, which mediates OA pain.
[0006] Angiogenesis is an important component of inflammation and pathogenesis in inflammatory bowel disease (IBD), which is divided into two major categories: ulcerative colitis (UC) and Crohn's disease (CD). Chronic inflammation and angiogenesis are closely related processes. In fact, immune / inflammatory cells secrete a variety of angiogenic factors (i.e., growth factors, cytokines). It has been found that VEGF levels in the serum of IBD patients are elevated, and their sources are inflammatory intestinal tissue and peripheral blood mononuclear cells. In IBD, physiological angiogenesis is transformed into pathological angiogenesis in the early stages of the disease. The factor or factors that lead to the transformation of physiological angiogenesis into pathological angiogenesis are still unclear (Angiogenesis in Inflammatory Bowel Disease–C.Alkim et al.-International Journal of Inflammation, Volume 2015, Article ID 970890). Summary of the invention
[0007] The inventors have surprisingly discovered a new class of compounds that exhibit a previously undescribed dual feature in terms of selective and potent inhibition of the VEGF receptors VEGFR-2 (commonly known as the KDR receptor) and Fyn (a member of the Src family).
[0008] Therefore, the present invention relates to an N-phenylcarbamoyl compound of formula (I) or a salt thereof
[0009]
[0010] in
[0011] A is
[0012] in
[0013] X is an optionally substituted group selected from the group consisting of a 5- or 6-membered heteroaryl ring, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, (5- or 6-membered heteroaryl)CO-, (phenyl)CO-, and a 5- or 6-membered saturated heterocyclic ring;
[0014] Y is an optionally substituted 5- or 6-membered heteroaryl ring;
[0015] B is selected from phenyl, 5- or 6-membered heteroaryl ring, 5- or 6-membered saturated heterocycle, azaspiro (C7-C 10 )alkyl and saturated (C3-C6)cycloalkyl-NH-;
[0016] R1 and R2 are optional and do not exist at the same time, and are independently selected from (C1-C3) alkyl and halogen.
[0017] This unprecedented feature makes this series of candidates very promising compounds for the treatment of diseases such as osteoarthritis and other diseases where the two kinases act synergistically with adverse effects. This series has a unique and surprising pharmacokinetic profile that facilitates high-dose local treatment without parallel increases in concentrations in the blood or unaffected tissues, ensuring an unprecedented safety profile.
[0018] Therefore, the present invention also relates to an N-phenylcarbamoyl compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament.
[0019]
[0020] in
[0021] A is
[0022] in
[0023] X is an optionally substituted group selected from the group consisting of a 5- or 6-membered heteroaryl ring, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, (5- or 6-membered heteroaryl)CO-, (phenyl)CO-, and a 5- or 6-membered saturated heterocyclic ring;
[0024] Y is an optionally substituted (C5-C6)heteroaryl ring;
[0025] B is selected from phenyl, 5- or 6-membered heteroaryl ring, 5- or 6-membered saturated heterocycle, azaspiro (C7-C 10 )alkyl and saturated (C3-C6)cycloalkyl-NH-;
[0026] R1 and R2 are optional and do not exist at the same time, and are independently selected from (C1-C3) alkyl or halogen.
[0027] On the other hand, the present invention also relates to formula (I)
[0028]
[0029] An N-phenylcarbamoyl compound or a pharmaceutically acceptable salt thereof for use in inhibiting at least one tyrosine kinase selected from Fyn and VEGFR2 in the treatment of diseases and disorders associated with one or two kinases,
[0030] in
[0031] A is
[0032] in
[0033] X is an optionally substituted group selected from the group consisting of a 5- or 6-membered heteroaryl ring, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, (5- or 6-membered heteroaryl)CO-, (phenyl)CO-, and a 5- or 6-membered saturated heterocyclic ring;
[0034] Y is an optionally substituted (C5-C6)heteroaryl ring;
[0035] B is selected from phenyl, 5- or 6-membered heteroaryl ring, 5- or 6-membered saturated heterocycle, azaspiro (C7-C 10 )alkyl and saturated (C3-C6)cycloalkyl-NH-;
[0036] R1 and R2 are optional and do not exist at the same time, and are independently selected from (C1-C3) alkyl or halogen.
[0037] Therefore, the compounds of formula (I) can also act as tyrosine kinase inhibitors of two kinases (Fyn and VEGFR), and are therefore dual kinase inhibitors. This multi-target therapy has therapeutic potential for the treatment of osteoarthritis and other pathologies and diseases associated with both kinases.
[0038] Specifically, the compounds of the present invention are disclosed for use in treating a condition / disease / pathology selected from the group consisting of osteoarthritis; eye diseases, such as intraocular neovascularization disorders, such as age-related macular degeneration, diabetic macular edema and other ischemia-related retinopathies or immune-mediated corneal transplant rejection; skin disorders, such as psoriasis or rosacea; acute or chronic pain; lung diseases, such as acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP) and systemic sclerosis (SSc); cancers, such as metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, recurrent glioblastoma multiforme, gynecological malignancies, metastatic breast cancer.
[0039] In a preferred aspect, the compounds of the present invention are disclosed for use in the treatment of acute and chronic pain, preferably selected from neuropathic pain, inflammatory pain, osteoarthritic pain, ocular pathology pain. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 : Local analgesic efficacy of compound 3 in the rat CFA test. Activity is reported as mechanical threshold (weight supported by the CFA inflamed paw). Also shown are naive rats treated with vehicle and test substance. Animal data to demonstrate no effect on normal pain thresholds.
[0041] Figure 2: Dose response curve of local analgesic efficacy of different doses of compound 3 in the rat CFA test. Activity is reported as mechanical threshold (weight borne by the CFA inflamed paw). DETAILED DESCRIPTION
[0042] The present invention relates to pharmaceutical compositions containing dual VEGF2 / Fyn inhibitors that can act locally to address diseases resistant to other drugs without causing general systemic toxicity.
[0043] Therefore, the present invention relates to an N-phenylcarbamoyl compound of formula (I) or a salt thereof
[0044]
[0045] in
[0046] A is
[0047] in
[0048] X is an optionally substituted group selected from the group consisting of a 5- or 6-membered heteroaryl ring, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, (5- or 6-membered heteroaryl)CO-, (phenyl)CO-, and a 5- or 6-membered saturated heterocyclic ring;
[0049] Y is an optionally substituted (C5-C6)heteroaryl ring;
[0050] B is selected from phenyl, 5- or 6-membered heteroaryl ring, 5- or 6-membered saturated heterocycle, azaspiro (C7-C 10 )alkyl and saturated (C3-C6)cycloalkyl-NH-;
[0051] R1 and R2 are optional and do not exist at the same time, and are independently selected from (C1-C3) alkyl or halogen.
[0052] In the present invention, when the following terms are used:
[0053] - "compound of the invention" or "compound of this invention" refers to a compound of formula (I) as defined above,
[0054] any form, i.e. any salt or non-salt form (e.g. as a free acid or free base form, or as a salt, in particular a pharmaceutically acceptable salt thereof) and any physical form thereof (e.g. including non-solid forms (e.g. liquid or semi-solid forms) and solid forms (e.g. amorphous or crystalline forms, specific polymorphic forms, solvate forms,
[0055] including hydrate forms (e.g., monohydrate, dihydrate and hemihydrate)) and mixtures of the various forms;
[0056] - "optionally substituted" refers to an unsubstituted group or ring, or a group or ring substituted with one or more of the specified substituents;
[0057] - "saturated 5- or 6-membered heterocycle" refers to a saturated carbocyclic ring in which one or two carbon atoms are replaced by heteroatoms (e.g. nitrogen, oxygen or sulfur); non-limiting examples are tetrahydropyran, pyrrolidine, imidazolidine, pyrazolidine, thiazolidine, tetrahydrofuran, 1,3-dioxolane, piperidine, piperazine and morpholine;
[0058] - "(C1-C3) alkyl" means a straight or branched chain saturated hydrocarbon group containing 1 to 3 carbon atoms;
[0059] - "(C1-C4) alkyl" means a straight or branched chain saturated hydrocarbon group containing 1 to 4 carbon atoms;
[0060] - "saturated (C3-C6) cycloalkyl" refers to a saturated 3- to 6-membered all-carbon monocyclic ring; non-limiting examples are cyclopropane, cyclobutane, cyclopentane, cyclohexane;
[0061] -"Azaspiro (C7-C 10 ) alkyl" refers to a saturated 8-10-membered ring consisting of carbon atoms and one nitrogen atom, forming a ring with a spiro atom;
[0062] - "halogen" means a chlorine atom, a fluorine atom, a bromine atom and an iodine atom;
[0063] - "5- or 6-membered heteroaryl ring" refers to an unsaturated carbocyclic ring in which 1 to 3 carbon atoms are replaced by heteroatoms (e.g. nitrogen, oxygen or sulfur); non-limiting examples are pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, thiadiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, indazolyl.
[0064] According to the present invention, A is
[0065] X is an optionally substituted group selected from the group consisting of a 5- or 6-membered heteroaryl ring, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, (5- or 6-membered heteroaryl)CO-, (phenyl)CO- and a 5- or 6-membered saturated heterocyclic ring;
[0066] X can be an optionally substituted 5- or 6-membered heteroaryl ring. The 5- or 6-membered heteroaryl ring is preferably pyrazine or pyridine or pyrimidine, optionally substituted by one or more substituents selected from the group consisting of (C1-C3) alkyl, (morpholinyl) methyl, (dimethylmorpholinyl) methyl, pyrrolidin-1-yl-methyl, 4-ethylpiperazine-1-yl, 4-(2-hydroxyethyl)piperazine-1-yl, 3-hydroxyazetidine-1-yl, 3-(dimethylamino)pyrrolidin-1-yl, (2-hydroxyethyl)-1H-pyrazol-4-yl, morpholin-1-yl and cyano; more preferably, the substituent (C1-C3) alkyl is methyl.
[0067] X may be an optionally substituted 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl group. When it is substituted, it is preferably substituted by one or more substituents selected from the group consisting of (C1-C3)alkyl, hydroxy(C1-C3)alkyl and ((C1-C3)alkyl)CO-, more preferably ethyl, 2-hydroxyethyl and acetyl.
[0068] X may be an optionally substituted (5- or 6-membered heteroaryl)CO-. Preferably, (5- or 6-membered heteroaryl)CO- is (pyridine)CO- or (pyrimidine)CO-. When it is substituted, it is preferably substituted by one or more (C1-C3)alkyl.
[0069] X may be an optionally substituted (phenyl)CO-. When it is substituted, it is preferably substituted by one or more substituents selected from the group consisting of halogen, (1-isopropylazetidin-3-yl)oxy, 4-methylpiperazine-1-yl and 1-methylpiperidin-4-yl. When it is halogen, more preferably fluorine.
[0070] Y is an optionally substituted (C5-C6) heteroaryl ring. The optionally substituted (C5-C6) heteroaryl ring is preferably an optionally substituted pyrazine, more preferably an unsubstituted pyrazine. When pyrazine is substituted, it is preferably substituted by one or more (C1-C3) alkyl, still more preferably substituted by methyl.
[0071] R1 and R2 are optional and do not exist at the same time, and are independently (C1-C3) alkyl or halogen. Preferably, R1 is (C1-C3) alkyl, more preferably methyl. Preferably, R2 is H or halogen. When R1 is halogen, preferably fluorine or chlorine, more preferably fluorine. When R2 is halogen, preferably fluorine.
[0072] B may be an optionally substituted phenyl. When B is a substituted phenyl, it is preferably substituted by one or more substituents selected from the group consisting of (C1-C3) alkyl, R'SO2-, R'R"N(C1-C3) alkyl, R'NH(C1-C3) alkyl, R'R"N-, trifluoromethyl, difluoromethyl, halogen, R'R"NSO2-, (C3-C6) cycloalkyl, (C3-C6) cycloalkyl-NH-, NR'(C3-C6) cycloalkyl, wherein R' and R" are independently (C1-C3) alkyl, more preferably methyl. Among the preferred substituents of phenyl, the following may be cited: CH3SO2-, -CH2N(CH3)2, CH3, CF3, CHF2, fluorine, -SO2N(CH3)2, (N-ethyl)aminocyclopropyl.
[0073] B can be an optionally substituted 5- or 6-membered heteroaryl ring. The optionally substituted 5- or 6-membered heteroaryl ring is preferably pyridine or oxazole. When the (C5-C6) heteroaryl ring is substituted, it is preferably substituted by one or more hydroxyl (C1-C3) alkyl, CF3, (C1-C4) alkyl, cyano (C1-C3) alkyl and (C3-C6) cycloalkyl-SO2-. Among the preferred substituents of the (C5-C6) heteroaryl ring, pyridine and oxazole are preferred, and the following can be cited: 2-cyanopropyl-2-yl, 2-cyanopropyl-2-yl, CH3, CF3, fluorine, isobutyl or cyclopropylsulfonyl.
[0074] B can be an azaspiro (C7-C 10 Preferably, it is azaspiro[3,4]octane or azaspiro[4,5]decane.
[0075] B may be an optionally substituted 5- or 6-membered saturated heterocyclic ring. Preferably, it is pyrrolidine, more preferably substituted by one or more (C1-C3)alkyl groups, still more preferably substituted by ethyl groups.
[0076] B may be an optionally substituted saturated (C3-C6) cycloalkyl-NH-. Preferably, it is 4,4-(dimethylcyclohexyl)-NH-, cyclopentyl-NH-.
[0077] In a preferred embodiment, A is
[0078] In this preferred embodiment, X is preferably an optionally substituted 5- or 6-membered heteroaryl ring, more preferably an optionally substituted pyrazine.
[0079] B is preferably optionally substituted phenyl, preferably substituted by CF3.
[0080] In a preferred aspect, the compound of formula (I) is selected from the group consisting of:
[0081] 1) N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(methylsulfonyl)benzamide,
[0082] 2) 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)isonicotinamide,
[0083] 3) N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0084] 4) 4-(1-(ethylamino)cyclopropyl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)benzamide,
[0085] 5) 2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)isonicotinamide,
[0086] 6) 2-methyl-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-5-(trifluoromethyl)oxazole-4-carboxamide,
[0087] 7) 2-fluoro-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-5-(trifluoromethyl)benzamide,
[0088] 8) 4-(cyclopropylsulfonyl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)picolinamide,
[0089] 9) N-(3-(2-fluoro-5-(6-isobutylnicotinamido)phenethyl)-1H-pyrazol-5-yl)pyrimidine-2-carboxamide,
[0090] 10) N-(4-fluoro-3-(2-(5-((2-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0091] 11) 2-(2-cyanopropan-2-yl)-N-(4-fluoro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)isonicotinamide,
[0092] 12) N-(4-fluoro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(methylsulfonyl)benzamide,
[0093] 13) N-(4-fluoro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0094] 14) N-(3-(2-(5-((3,5-dimethylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-fluorophenyl)-3-(trifluoromethyl)benzamide,
[0095] 15) N-(4-fluoro-3-(2-(5-((3-methylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0096] 16) N-(4-chloro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0097] 17) N-(3-(2-(5-((2-ethyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide,
[0098] 18) N-(5-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenethyl)-1H-pyrazol-3-yl)picolinamide,
[0099] 19) N-(3-(2-(3-(4-fluorobenzamido)-1H-pyrazol-5-yl)ethyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide,
[0100] 20) N-(4-methyl-3-(2-(5-((3-methylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-6-azaspiro[3.4]octane-6-carboxamide,
[0101] 21) 3,3-Diethyl-N-(4-methyl-3-(2-(5-((3-methylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)pyrrolidine-1-carboxamide
[0102] 22) 3,3-Diethyl-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)pyrrolidine-1-carboxamide
[0103] 23) N-(3-(5-(3-(4,4-dimethylcyclohexyl)ureido)-2-methylphenethyl)-1H-pyrazol-5-yl)-4-((1-isopropylazetidin-3-yl)oxy)benzamide,
[0104] 24) N-(3-(5-(3-cyclopentylureido)-2-methylphenethyl)-1H-pyrazol-5-yl)-4-(4-methylpiperazin-1-yl)benzamide,
[0105] 25) N-(3-(5-(3-(4,4-dimethylcyclohexyl)ureido)-2-methylphenethyl)-1H-pyrazol-5-yl)-4-(1-methylpiperidin-4-yl)benzamide,
[0106] 26) N-(4-fluoro-3-(2-(3-((2-methyl-6-(morpholinomethyl)pyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0107] 27) N-(3-(2-(3-((6-(((2S,6R)-2,6-dimethylmorpholinyl)methyl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)-4-fluorophenyl)-3-(trifluoromethyl)benzamide,
[0108] 28) N-(4-fluoro-3-(2-(3-((2-methyl-6-(pyrrolidin-1-ylmethyl)pyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0109] 29) N-(3-(2-(3-((6-(4-ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)-4-fluorophenyl)-3-(trifluoromethyl)benzamide,
[0110] 30) N-(4-fluoro-3-(2-(3-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0111] 31) N-(4-fluoro-3-(2-(3-((6-(3-hydroxyazetidin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0112] 32)(S)-N-(3-(2-(3-((6-(3-(dimethylamino)pyrrolidin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)-4-fluorophenyl)-3-(trifluoromethyl)benzamide,
[0113] 33) 3-(difluoromethyl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)benzamide,
[0114] 34) N-(3-(2-(5-((2-acetyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide,
[0115] 35) 3-(isopropylsulfonyl)-N-(4-methyl-3-(2-(5-((3-methylpyridin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)benzamide,
[0116] 36) 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(5-((3-methylpyridin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)isonicotinamide,
[0117] 37) N-(3-(2-(5-((6-cyano-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-3-(N,N-dimethylsulfamoyl)benzamide,
[0118] 38) N-(3-(2-(5-((6-cyano-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-8-azaspiro[4.5]decane-8-carboxamide,
[0119] 39) N-(3-(2-(5-((6-cyano-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-fluorophenyl)-4-((dimethylamino)methyl)-3-(trifluoromethyl)benzamide,
[0120] 40) N-(4-fluoro-3-(2-(5-((2-methylpyrimidin-5-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0121] 41) 4-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)picolinamide,
[0122] 42) N-(4-fluoro-3-(2-(3-((6-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0123] 43) N-(2-fluoro-5-(2-(5-((2-methyl-6-morpholinopyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0124] 44) N-(2-fluoro-5-(2-(3-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0125] 45) N-(5-(2-(3-((6-(4-ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)-2-fluorophenyl)-3-(trifluoromethyl)benzamide,
[0126] 46) N-(2-fluoro-5-(2-(3-((6-(3-hydroxyazetidin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0127] 47) 4-((dimethylamino)methyl)-N-(3-(2-(5-(4-morpholinylbenzamido)-1H-pyrazol-3-yl)ethyl)phenyl)benzamide,
[0128] 48) N-(4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)-3-(methylsulfonyl)benzamide,
[0129] 49) N-(4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, and
[0130] 50) 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)isonicotinamide.
[0131] More preferably, the compound of formula (I) is selected from the group consisting of:
[0132] 3) N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0133] 6) 2-methyl-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-5-(trifluoromethyl)oxazole-4-carboxamide,
[0134] 8) 4-(cyclopropylsulfonyl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)picolinamide,
[0135] 13) N-(4-fluoro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0136] 15) N-(4-fluoro-3-(2-(5-((3-methylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide,
[0137] 34) N-(3-(2-(5-((2-acetyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide,
[0138] 49) N-(4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, and
[0139] More preferably, the compound of the present invention is 3) N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide.
[0140] The compounds of the present invention may be in the form of salts, preferably pharmaceutically acceptable salts. Therefore, any acid addition salts or base addition salts are included in the present invention as long as they are pharmaceutically acceptable salts.
[0141] As examples, salts derived from inorganic bases include aluminum salts, ammonium salts, calcium salts, copper salts, ferric salts, ferrous salts, lithium salts, magnesium salts, manganous salts, potassium salts, sodium salts, zinc salts, etc. Preferred are ammonium salts, calcium salts, magnesium salts, lithium salts, potassium salts and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases may also be included, such as salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethyl-aminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methyl-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
[0142] Pharmaceutically acceptable salts can be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, etc. Particularly preferred are citric acid, hydrobromic acid, hydrochloric acid, maleic acid, phosphoric acid, sulfuric acid and tartaric acid.
[0143] The general scheme for preparing the compounds of the present invention is summarized as follows:
[0144]
[0145] The process outlined in Scenario 1 includes the following steps:
[0146] a) converting compound II (Z=Br) into compound III (Y=H) by adding ammonia in the presence of copper iodide; or converting compound II (Z=Br) into compound III (Y=COR3) by adding benzamide NH2COR3 in the presence of an organic metal catalyst (e.g., tris(dibenzylideneacetone)dipalladium(0)); or converting compound II (Z=NH2) into compound III (Y=COOtBu) by adding di-tert-butyl dicarbonate in a dichloromethane solvent;
[0147] b) converting compound III to compound IV by adding a halogenated heterocycle X-R2 in the presence of an organic metal catalyst (e.g., tris(dibenzylideneacetone)dipalladium(0)); or converting compound III to compound IV by amide coupling using a standard coupling agent (e.g., N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride and dimethylaminopyridine) in a dichloromethane solvent;
[0148] c) when Y = COOtBu, remove the tert-butyloxycarbonyl protecting group using HCl or trifluoroacetic acid in dichloromethane solvent;
[0149] d) amide coupling using standard coupling reagents or urea formation using reagents such as carbonyldiimidazole dissolved in tetrahydrofuran to give compound VI;
[0150] e) removing the protecting group using formic acid to obtain compound I; and
[0151] f) When Y = COR3, the protecting group is removed with formic acid to give a compound of formula (I).
[0152] Specifically, the general syntheses for preparing compounds of formula (I) are described in Schemes 1-4.
[0153] The steps of scenario 1 are reported as follows:
[0154] Solution 1
[0155]
[0156] The process outlined in Scenario 1 includes the following steps:
[0157] a1) converting compound V to compound VI by adding a halogenated heterocycle in the presence of an organic metal catalyst (e.g., tris(dibenzylideneacetone)dipalladium(0)); or converting compound V to compound VI by amide coupling using a standard coupling agent (e.g., N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride and dimethylaminopyridine) in a dichloromethane solvent;
[0158] b1) removing the tert-butyloxycarbonyl protecting group using HCl or trifluoroacetic acid in a dichloromethane solvent;
[0159] c1) amide coupling using standard coupling reagents or urea formation using reagents such as carbonyldiimidazole in tetrahydrofuran to provide compound VIII; and
[0160] d1) removing the protecting group with formic acid to obtain compound I.
[0161] The steps of scenario 2 are reported as follows:
[0162] Solution 2
[0163]
[0164] a2) converting compound IX to compound X by adding benzamide in the presence of an organometallic catalyst (e.g. tris(dibenzylideneacetone)dipalladium(0));
[0165] b2) removing the protecting group with formic acid to obtain compound XI;
[0166] c2) Compound XI is converted to compound I by adding a halogenated heterocycle in the presence of an organometallic catalyst such as tris(dibenzylideneacetone)dipalladium(0).
[0167] Another embodiment of the present invention for obtaining compounds of formula (I) is depicted in Scheme 3 below:
[0168] Solution 3
[0169]
[0170] The process outlined in Scenario 3 includes the following steps:
[0171] a3) converting compound XII to amine XIII using ammonia in a sealed tube at 100° C. in the presence of copper iodide as a catalyst;
[0172] b3) using a standard coupling agent to carry out amide coupling to obtain compound XIV;
[0173] c3) converting compound XIV to compound XV by adding a halogenated heterocycle in the presence of an organometallic catalyst (e.g., tris(dibenzylideneacetone)dipalladium(0)); or converting compound XV to compound XV by amide coupling using a standard coupling reagent (e.g., N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride and dimethylaminopyridine) in a dichloromethane solvent;
[0174] d3) removing the protecting group with formic acid to obtain compound I.
[0175] The steps of scenario 4 are reported as follows:
[0176] Solution 4
[0177]
[0178] The process outlined in Scenario 4 includes the following steps:
[0179] a4) converting compound XVI to compound XVII by adding a halogenated heterocycle in the presence of an organometallic catalyst (e.g., tris(dibenzylideneacetone)dipalladium(0)); or converting compound XVI to compound XVII by amide coupling using a standard coupling agent (e.g., N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride and dimethylaminopyridine) in a dichloromethane solvent;
[0180] b4) removing the BOC protecting group using HCl or trifluoroacetic acid in dichloromethane solvent;
[0181] c4) Amide coupling using standard coupling reagents to give compound I.
[0182] The compounds of formula (I) as described above are useful as medicaments.
[0183] In another aspect, the present invention relates to formula (I)
[0184]
[0185] An N-phenylcarbamoyl compound or a pharmaceutically acceptable salt thereof for use as a medicament.
[0186] in
[0187] A is
[0188] in
[0189] X is an optionally substituted group selected from the group consisting of a 5- or 6-membered heteroaryl ring, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, (5- or 6-membered heteroaryl)CO-, (phenyl)CO-, and a saturated (C5-C6) heterocycle;
[0190] Y is an optionally substituted (C5-C6)heteroaryl ring;
[0191] B is selected from phenyl, 5- or 6-membered heteroaryl ring, 5- or 6-membered saturated heterocycle, azaspiro (C7-C 10 )alkyl and saturated (C3-C6)cycloalkyl-NH-;
[0192] R1 and R2 are optional and do not exist at the same time, and are independently selected from (C1-C3) alkyl and halogen.
[0193] The current trend in the development of tyrosine kinase inhibitors is based on the assumption that multitargeted therapies that simultaneously target multiple signaling pathways are more effective than single targeted therapies. In cancer, considerations that determine whether multiple single kinase inhibitors or a single multikinase inhibitor are preferable are based on aspects related to efficacy, drug resistance, pharmacokinetics, selectivity, and tumor environment. OA is clinically characterized by symptoms (mainly pain) and pathological changes in joint structure, which together determine functional impairment, so multitargeted therapy with tyrosine kinase inhibitors has therapeutic potential for the treatment of OA.
[0194] Therefore, in another aspect, the present invention also relates to formula (I)
[0195]
[0196] An N-phenylcarbamoyl compound or a pharmaceutically acceptable salt thereof for inhibiting at least one tyrosine kinase selected from Fyn and VEGFR2 in the treatment of diseases and conditions associated with one or two kinases,
[0197] in
[0198] A is
[0199] in
[0200] X is an optionally substituted group selected from the group consisting of a 5- or 6-membered heteroaryl ring, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, (5- or 6-membered heteroaryl)CO-, (phenyl)CO-, and a 5- or 6-membered saturated heterocyclic ring;
[0201] Y is an optionally substituted (C5-C6)heteroaryl ring;
[0202] B is selected from phenyl, 5- or 6-membered heteroaryl ring, 5- or 6-membered saturated heterocycle, azaspiro (C7-C 10 )alkyl and saturated (C3-C6)cycloalkyl-NH-;
[0203] R1 and R2 are optional and do not exist at the same time, and are independently selected from (C1-C3) alkyl or halogen.
[0204] Specifically, surprisingly, the compounds of formula (I) are useful for treating osteoarthritis. Without being bound by any theory, the inventors believe that compounds targeting two kinases, Fyn and VEGFR2, which appear to be critical in determining the symptoms and progression of OA, appear to be ideal candidates, overcoming the classical dichotomy between structural and symptom modulators. In addition, the intra-articular mode of action of the compound (providing maximum concentrations in peripheral sites) and poor systemic availability allow for the prediction of good efficacy without possible systemic safety issues. Reduced systemic drug exposure may be particularly relevant to patients with complex or severe comorbidities.
[0205] According to the invention, the compounds are used to treat other conditions in which local and concomitant inhibition of VEGF- and Fyn would be beneficial. In particular, they include eye diseases, such as intraocular neovascularization disorders, such as age-related macular degeneration, diabetic macular edema and other ischemia-related retinopathy, or immune-mediated corneal transplant rejection; skin diseases, such as psoriasis (a common autoimmune disease characterized by epidermal hyperplasia and dermal hypervascularization); or rosacea (a common chronic disease that mainly affects the facial skin, characterized by visible blood vessels, central facial erythema and usually papules and pustules); acute or chronic pain, lung diseases, such as acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP) and systemic sclerosis (SSc); and certain cancers, such as metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, recurrent glioblastoma multiforme, gynecological malignancies, metastatic breast cancer.
[0206] In a preferred aspect, the compounds of the present invention are disclosed for use in the treatment of acute and chronic pain selected from neuropathic pain, inflammatory pain, osteoarthritic pain, ocular pathology pain.
[0207] Preferably, the composition of the present invention is used in a pharmaceutical composition together with pharmaceutically acceptable carriers and excipients.
[0208] Therefore, the composition may further comprise a pharmaceutically acceptable excipient and may be administered in a pharmaceutical form suitable for the desired administration route.
[0209] Pharmaceutically acceptable additives may be excipients, ligands, dispersants, colorants, wetting agents, and are generally used to prepare tablets, capsules, pills, solutions, suspensions, emulsions for oral administration. Injectable solutions are also contemplated for parenteral administration, including subcutaneous, spinal and transdermal administration.
[0210] The pharmaceutical composition according to the present invention is preferably used for intra-articular, intravenous, oral, transdermal, intrathecal, intranasal, intraperitoneal or intramuscular administration, more preferably intra-articular administration.
[0211] The preferred dosage range of the compound of formula (I) of the present invention is 0.25mg / knee to 500mg / knee, and the more preferred dosage range is 1mg / knee to 200mg / knee. These dosages can be dissolved in a volume within the range of 0.5mL / knee to 6mL / knee. The pharmaceutical composition according to the present invention can be used alone, or used in combination with one or more other drugs, or can contain one or more other drugs. These drugs include but are not limited to hyaluronic acid, chondroitin sulfate and glucosamine, glucosamine sulfate and steroidal or non-steroidal anti-inflammatory drugs.
[0212] The present invention will now be described in detail with reference to examples of preparation of the compounds of the present invention and examples for testing inhibitory activity, which examples are intended to be illustrative rather than limiting.
[0213] Experimental Section
[0214] The reagents used in the following examples were purchased from various suppliers and used without further purification. The solvents were used in dry form. Reactions in anhydrous environments were carried out under a positive pressure of dry N2.
[0215] Proton NMR was recorded on a Bruker Avance 400 MHz instrument ( 1 H NMR) spectra. Chemical shifts are reported in ppm (δ) using the residual solvent line as an internal standard. Splitting patterns are designated as: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad signal.
[0216] Mass spectrometry (MS) was run on an lon Trap Thermo LCQ Classic spectrometer operating in both positive ES (+) and negative ES (-) ionization modes.
[0217] UPLC spectrometric analysis was performed on a Waters Acquity UPLC-SQD instrument using an Acquity UPLC-BEH C18 column (1.7 μM, 50 x 2.1 mm).
[0218] Chiral-HPLC spectroscopy was performed using an Agilent 1200 instrument equipped with a UV-Vis detector.
[0219] Preparative HPLC was performed on a Waters GX-281 HPLC system equipped with a UV detector.
[0220] Flash silica chromatography was performed on a Biotage automated flash chromatography system (Sp1 and Isolera systems) using either Biotage SNAP HP silica columns or Biotage SNAP KP-NH columns.
[0221] Reverse phase chromatography was performed on a Biotage automated flash chromatography system (Isolera system) using a RediSep Gold C-18Aq column.
[0222] Some basic compounds were purified using a Phenomenex Strata SCX column (55 μm, 70 A).
[0223] Thin layer chromatography analysis was performed using Merck thin layer chromatography plates Kieselgel 60F-254, and observation was performed using UV light, aqueous permanganate solution, and iodine vapor.
[0224] Microwave reactions were performed on a Biotage Initiator apparatus.
[0225] The following abbreviations are used in this paper: CAN: acetonitrile; AcOH: acetic acid; CDI: carbonyldiimidazole; cHex: cyclohexane; DIAD: diisopropyl (E)-diazene-1,2-dicarboxylate; Boc: tert-butyloxycarbonyl; Boc2O: di-tert-butyl dicarbonate; DCM: dichloromethane; DCE: 1,2-dichloroethane; TFA: trifluoroacetic acid; DMF: dimethylformamide; THF: tetrahydrofuran; RT: room temperature; DMAP: dimethylaminopyridine; AcOEt: ethyl acetate Ester; NaOH: sodium hydroxide; KOH: potassium hydroxide; DIPEA: N,N-diisopropylethylamine; TEA: triethylamine; NaHCO3: sodium bicarbonate; Na2SO4: sodium sulfate; PdCl2(PPh3)2: bis(triphenylphosphine)palladium(II) chloride; Cs2CO3: cesium carbonate; DIBAL-H: diisobutylaluminum hydride; LAH: lithium aluminum hydride; tBuOK: potassium tert-butoxide; iPr2O: diisopropyl ether; DIBAL-H: diisobutylaluminum hydride.
[0226] In the following schemes (5, 6, 7 and 8), general synthetic routes to the intermediates (V, IX, XII, XVI) of Schemes 1, 2, 3 and 4 are described.
[0227] Scheme 5 to obtain intermediate (V) is reported below:
[0228] Solution 5
[0229]
[0230] Solution 5 provides the following steps:
[0231] a) converting the starting material in the compound of formula XVI using a reducing agent (e.g. DIBAL-H in DCM solvent);
[0232] R1 can be =F, Cl, Me;
[0233] b) In water, use ethyl 2-(triphenylphosphoranylidene)acetate
[0234] Perform a Wittig reaction to obtain intermediate XVII;
[0235] c) reducing the double bond and the nitro group under hydrogen atmosphere and amine protection to obtain an intermediate of formula XVIII;
[0236] d) The aminopyrazole derivative (V) is formed using tert-butylhydrazine in a polar solvent such as ethanol.
[0237] Solution 6
[0238]
[0239] Solution 6 provides the following steps:
[0240] a) reducing the double bond under hydrogen atmosphere to obtain intermediate XIX;
[0241] b) The aminopyrazole derivative IX is formed using tert-butylhydrazine in a polar solvent such as ethanol.
[0242] Solution 7
[0243]
[0244] Solution 7 provides the following steps:
[0245] a) Ester formation using thionyl chloride in MeOH;
[0246] b) The aminopyrazole derivative (XII) is formed using tert-butylhydrazine in a polar solvent such as ethanol.
[0247] Solution 8
[0248]
[0249] Solution 8 provides the following steps:
[0250] a) protecting the starting material amine to obtain intermediate XXI;
[0251] b) converting the intermediate of formula XXI into compound XXII using ethyl acrylate in the presence of a palladium catalyst and triphenylphosphine;
[0252] c) Reduction of the double bond in EtOH / ethyl acetate under a hydrogen atmosphere:
[0253] d) reducing the ester group using a reducing agent (e.g. LAH dissolved in THF);
[0254] e) oxidizing the intermediate XXIV using an oxidizing agent (e.g., MnO2) to give the aldehyde XXV;
[0255] f) reacting intermediate XXV with 1-((chloromethyl)sulfonyl)-4-methylbenzene in a base (e.g. tBuOK in THF) to give intermediate XXVI;
[0256] g) forming bromoaldehyde XXVII using MgBr2;
[0257] h) Intermediate XVI is formed by reaction of intermediate XXVII with thiourea in THF / water.
[0258] Embodiment 1:
[0259] Preparation of Intermediate (XVI) of Scheme 5 (Intermediate 1-3)
[0260] General Procedure 1
[0261] At -78 ° C, 1M DIBAL-H dissolved in DCM (67.6 mL, 67.6 mmol) was added dropwise to a stirred solution of nitrobenzoate (56.4 mmol) in DCM (300 ml). After stirring at -78 ° C for 20 min, a mixture of DCM (150 mL) and saturated Rochelle salt solution (250 mL) was added. After vigorous stirring at room temperature for 1 hour, the resulting mixture was separated. The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the title compound as a clear oil.
[0262] Table 1
[0263] Intermediate 1-3: Intermediate (XVI) of Scheme 5
[0264]
[0265] Embodiment 2:
[0266] Preparation of Intermediate (XVII) of Scheme 5 (Intermediate 4-6)
[0267] General Procedure 2
[0268] A mixture of ethyl 2-(triphenylphosphinoalkylidene)acetate (21.09 g, 60.6 mmol) and nitrobenzaldehyde (60.6 mmol) in water was heated at 90 °C for 1 h.
[0269] The suspension is cooled to room temperature, extracted with DCM, and dried and concentrated with Na2SO4. The crude product is suspended in a mixture of cyclohexane and DCM, and the precipitation is removed by filtration. The concentrated filtrate is purified by silica gel column (340 g) and purification, eluted with cyclohexane to 8 / 2 cyclohexane / AcOEt to obtain the title compound as a yellow solid.
[0270] Table 2
[0271] Intermediate 4-6: Intermediate (XVII) of Scheme 5
[0272]
[0273]
[0274] Embodiment 3:
[0275] Preparation of Intermediate (XVIII) of Scheme 5 (Intermediate 7-9)
[0276] General Procedure 3
[0277] To a solution of intermediate 4-6 (17.00 mmol) in THF (75 ml) were added BOC2O (4.45 g, 20.41 mmol) and Pd / C (0.452 g, 0.425 mmol) The resulting solution was stirred under hydrogen atmosphere for 16 hours.
[0278] The mixture was filtered to remove the catalyst, then the filtrate was concentrated and purified on a silica gel column (100 g), 7CV, eluting with cHex only to 9:1 cHex / AcOEt to give the title compound as an off-white solid.
[0279] Table 3
[0280] Intermediates 7-9: Intermediates (XVIII) of Scheme 5
[0281]
[0282] Embodiment 4:
[0283] Preparation of Intermediate (V) (Intermediate 10-14) of Scheme 5
[0284] General Procedure 4
[0285] Acetonitrile (1.444 ml, 27.7 mmol) was added dropwise to a solution of nBuLi in hexane (11.06 ml, 27.7 mmol) in dry THF (52.7 ml) at -78°C, keeping the temperature below -65°C. After the addition was complete, the reaction was stirred at -78°C for 1 hour. After this, a solution of intermediate 7, 8 or 9 (11.06 mmol) in THF (10 ml) was added dropwise again, keeping the temperature below -65°C. After the addition was complete, the reaction was stirred at -78°C for 1 hour. After this, the reaction was quenched with 10% w / v aqueous citric acid (20 ml) and heated to room temperature. 1M HCl (20 ml) was then added until the pH was 3, and the product was extracted twice with iPr2O. The organic phase was washed with brine, dried, and evaporated under reduced pressure to give a yellow oil. The intermediate was dissolved in ethanol (105 ml), then hydrazine hydrochloride or tert-butylhydrazine hydrochloride (33.2 mmol) was added, and the resulting mixture was heated under reflux for 3 h.
[0286] The reaction was cooled to RT and ethanol was evaporated in vacuo. DCM (40 ml) and water / NaHCO were added to the remaining residue. After brief mixing, the two layers were separated and the organic layer was then dried over anhydrous sodium sulfate and evaporated. The resulting residue was loaded on a silica gel column (100 g; gradient: from DCM to 9 / 1 DCM / iPrO) to obtain the title compound as an off-white solid.
[0287] Table 4
[0288] Intermediates 10-14: Intermediates (V) of Scheme 5
[0289]
[0290] Embodiment 5:
[0291] Preparation of Intermediate (XIX) (Intermediate 15) of Scheme 6
[0292] Methyl 3-(3-bromo-4-fluorophenyl)propanoate
[0293]
[0294] To a solution of (E)-methyl 3-(3-bromo-4-fluorophenyl)acrylate (5.3 g, 20.46 mmol) in THF (30 ml) was added 5% rhodium on carbon (1.179 g, 0.573 mmol) The resulting solution was placed under a hydrogen atmosphere (1 bar; RT).
[0295] The reaction was filtered to remove the catalyst. The filtrate was then concentrated under vacuum to remove the solvent. Yield: 5.34 g (yellow oil).
[0296] 1H NMR (400MHz, DMSO-d6) δppm 7.55-7.64(1H,m),7.22-7.34(2H,m),3.53-3.65(3H,m),2.79-2.91(2H,m),2.59-2.72(2H,m).
[0297] ESI+m / z 262[M+H]
[0298] Embodiment 6:
[0299] Preparation of Intermediate (IX) (Intermediate 16) of Scheme 6
[0300] 3-(3-Bromo-4-fluorophenyl)-1-(tert-butyl)-1H-pyrazol-5-amine
[0301]
[0302] At -78 ° C, in dry THF (100 ml), acetonitrile (2.314 ml, 44.3 mmol) was added dropwise to a solution of n-butyl lithium in hexane (17.72 ml, 44.3 mmol), keeping the temperature below -65 ° C. After the addition was complete, the reaction was stirred at -78 ° C for 1 hour. Thereafter, 3-(3-bromo-4-fluorophenyl)methyl propionate (5.34 g, 22.15 mmol) was added dropwise, keeping the temperature below -65 ° C. After the addition was complete, the reaction was stirred at -78 ° C for 1 hour. Afterwards, the reaction was quenched with 1M HCl aqueous solution (5 ml). The reaction was warmed to RT, and then the organic solvent was removed under vacuum.
[0303] To the remaining solution was added 1 M aqueous HCl (15 ml) followed by DCM (50 ml).After brief mixing, the organic layer was separated, dried over anhydrous sodium sulfate and evaporated to a yellow oil.
[0304] To this yellow oil, ethanol (150ml) was added, followed by tert-butylhydrazine hydrochloride (4.14g, 33.2mmol) and sodium hydroxide (1.240g, 31.0mmol). The resulting mixture was then heated to reflux overnight. The next day, the reaction was cooled to RT and then ethanol was removed. Water (50ml), saturated sodium bicarbonate aqueous solution (50ml) and DCM (100ml) were added to the remaining residue. After brief mixing, the organic layer was separated, dried over anhydrous sodium sulfate, and then evaporated to a brown oil. Purification: KP-NH silica gel column (110g), eluted with 70:30cyHex / DCM. Yield: 6.64g (yellow solid).
[0305] 1H NMR (400MHz, DMSO-d6) δppm 7.55(1H,dd),7.21-7.28(2H,m),5.20(1H,s),4.72(2H,s),2.74-2.86(2H,m),2.54-2.65(2H,m),1.49(9H,s).
[0306] ESI+m / z 341[M+H]
[0307] Embodiment 7:
[0308] Preparation of Intermediate (XX) (Intermediate 17) of Scheme 7
[0309] Methyl 3-(3-bromophenyl)propionate
[0310]
[0311] To a solution of 3-(3-bromophenyl)propanoic acid (5 g, 21.83 mmol) in dry methanol (44 ml) was added sulfur dichloride (4.75 ml, 65.5 mmol). After the addition was complete, the reaction was heated to RT and allowed to stand overnight. After stirring overnight, the reaction was evaporated and dried under high vacuum. Yield 5.35 g (colorless oil).
[0312] 1 H NMR (400MHz, DMSO-d6) δppm 7.35-7.50(2H,m),7.21-7.28(2H,m),3.59(3H,s),2.77-2.91(2H,m),2.59-2.70(2H,m).
[0313] ESI+m / z 245[M+H]
[0314] Example 8
[0315] Preparation of Intermediate (XII) (Intermediate 18) of Scheme 7
[0316] 3-(3-Bromophenethyl)-1-(tert-butyl)-1H-pyrazol-5-amine
[0317]
[0318] Acetonitrile (2.338 ml, 44.8 mmol) was added dropwise to a solution of nBuLi in hexane (17.90 ml, 44.8 mmol) in dry Et2O (100 ml) at -78°C, keeping the temperature below -65°C. After the addition was complete, the reaction was stirred at -78°C for 1 hour. After this, intermediate 17 (5.44 g, 22.38 mmol) was added dropwise, keeping the temperature below -65°C. After the addition was complete, the reaction was stirred at -78°C for 1 hour. Therefore, the reaction was quenched with 1M aqueous HCl (20 ml), heated to RT, and then the organic solvent was removed under vacuum.
[0319] To the remaining aqueous solution was added more 1 M aqueous HCl (35 ml) followed by DCM (50 ml).The organic phase was then dried over anhydrous sodium sulfate and evaporated to a yellow-brown oil.
[0320] The intermediate was dissolved in ethanol (200 ml), followed by the addition of tert-butylhydrazine hydrochloride (4.18 g, 33.6 mmol) and NaOH (1.253 g, 31.3 mmol). The resulting mixture was heated to reflux for 3 h, then cooled to RT and the ethanol evaporated under vacuum. DCM (100 ml) and dilute aqueous sodium bicarbonate solution were added to the remaining residue. After brief mixing, the two layers were separated and the organic layer was dried over anhydrous sodium sulfate. Purification: KP-NH silica gel column (110 g), eluted with a gradient of 9:1 cyclohexane / DCM to 1:1 cyclohexane / DCM. Produced 5.60 g (off-white solid)
[0321] 1 H NMR (400MHz, CDCl3) δppm 7.39(d,J=1.5Hz,1H),7.33(td,J=2.2,6.8Hz,1H),7.16(s,1H),7.15(s,1H),5.37(s,1H),2.94-2.88(m,2H),2.85-2.77(m,2H),1.65(s,9H).
[0322] ESI+m / z 323[M+H]
[0323] Example 9
[0324] Preparation of Intermediate (XXI) (Intermediate 19) of Scheme 8
[0325] tert-Butyl (3-bromo-4-methylphenyl)carbamate
[0326]
[0327] To a solution of 3-bromo-4-methylaniline (50.0 g, 0.269 mol), NaHCO (45.2 g, 0.538 mol) in MeOH (300 mL) and H O (150 mL) was slowly added Boc O (70.0 g, 0.322 mol) at 20-30°C, and the mixture was stirred at room temperature for 16 h. The mixture was then concentrated, and the crude product was diluted with DCM (800 mL), filtered and washed with H O (2*100 mL). The combined organics were dried over Na SO and concentrated to yield 74.5 g of the title intermediate as a white solid.
[0328] ESI+m / z 286[M+H]
[0329] Example 10
[0330] Preparation of Intermediate (XXII) (Intermediate 20) of Scheme 8
[0331] (E)-3-(5-((tert-Butyloxycarbonyl)amino)-2-methylphenyl)ethyl acrylate
[0332]
[0333] To a solution of intermediate 19 (74.5 g, 0.26 mol), TEA (105.0 g, 1.04 mol) and ethyl acrylate (260.0 g, 2.6 mol) in toluene (600 ml) was added Pd(OAc)2 / PPh3 (5.0 g / 13.6 g) at room temperature, and the mixture was stirred for 4 days at 112° C. The mixture was concentrated and purified by flash chromatography on silica gel (50:1 to 5:1 petroleum ether:AcOEt) to give the title intermediate (75 g) as a white solid.
[0334] ESI+m / z 306[M+H]
[0335] Embodiment 11
[0336] Preparation of Intermediate (XXIII) (Intermediate 21) of Scheme 8
[0337] Ethyl 3-(5-((tert-Butyloxycarbonyl)amino)-2-methylphenyl)propanoate
[0338]
[0339] To a solution of intermediate 20 (75.0 g, 0.245 mol) in ethyl acetate (600 mL) and ethanol (1200 mL) was added Pd / C (6.0 g, 10%), and the mixture was stirred under hydrogen atmosphere (50 psi) at 35° C. for 2 days. The mixture was filtered and concentrated to give intermediate 21 (65 g) as a light grey solid.
[0340] ESI+m / z 308[M+H]
[0341] Example 12
[0342] Preparation of Intermediate (XXIV) (Intermediate 22) of Scheme 8
[0343] tert-Butyl (3-(3-hydroxypropyl)-4-methylphenyl)carbamate
[0344]
[0345] To a solution of intermediate 21 (8.0 g, 26.0 mmol) in THF (30 mL) was added a solution of LiAlH4 (1.0 g, 26.0 mmol) in Et2O (30 mL) at 0-5°C, and the mixture was stirred at RT for 3 hours. The mixture was quenched with 1 mL of H2O, followed by 1 mL of 15% NaOH and 3 mL of H2O, filtered, and the filtrate was concentrated to yield intermediate 22 (6.9 g) as a white solid. ESI+m / z 266 [M+H]
[0346] Example 13
[0347] Preparation of Intermediate (XXV) (Intermediate 23) of Scheme 8
[0348] tert-Butyl (4-methyl-3-(3-oxopropyl)phenyl)carbamate
[0349]
[0350] PCC (1.2 g, 18.3 mmol) was added to a solution of crude intermediate 22 (6.9 g, 26.0 mmol) in dry DCM (100 mL), and the mixture was stirred overnight at RT. After completion of the reaction, the mixture was concentrated and purified by flash chromatography on silica gel (petroleum ether:AcOEt from 30:1 to 10:1) to give the title intermediate (3.5 g) as a yellow oil.
[0351] ESI+m / z 264[M+H]
[0352] Embodiment 14
[0353] Preparation of Intermediate (XXVI) (Intermediate 24) of Scheme 8
[0354] (4-methyl-3-(2-(3-tosyloxane-2-yl)ethyl)phenyl)amino Tert-butyl ester
[0355]
[0356] To a solution of intermediate 23 (20.0 g, 0.076 mol) in THF (200 ml) was added 1-((chloromethyl)sulfonyl)-4-toluene (18.6 g, 0.09 mol). After cooling to -65 °C, t-BuOK (10.0 g, 0.09 mol) was added to the solution in portions. The reaction was stirred at this temperature for 0.5 h and then at 0 °C for 0.5 h. The reaction was quenched with AcOH / water, EtOAc (100 mL) was added, and the mixture was washed with water and then with brine.
[0357] Purification: flash chromatography on silica gel (40:1 petroleum ether:AcOEt) afforded the title intermediate as a yellow solid (13.0 g).
[0358] ESI+m / z 432[M+H]
[0359] Embodiment 15
[0360] Preparation of Intermediate (XXVII) (Intermediate 25) of Scheme 8
[0361] tert-Butyl (3-(3-bromo-4-oxobutyl)-4-methylphenyl)carbamate
[0362]
[0363] To a solution of intermediate 24 (8.0 g, 18.5 mmol) in Et2O (300 mL) was added MgBr2.Et2O (6.0 g, 23.0 mmol). After 18 h at RT, water (50 mL) was added and the reaction was filtered. The filtrate was separated, the organic phase was washed with water, brine, dried over Na2SO4 and evaporated to yield the title intermediate (6.0 g) as a yellow solid.
[0364] ESI+m / z 357[M+H]
[0365] Example 16
[0366] Preparation of Intermediate (XVI) (Intermediate 26) of Scheme 8
[0367] tert-Butyl (3-(2-(2-aminothiazol-5-yl)ethyl)-4-methylphenyl)carbamate
[0368]
[0369] To a solution of intermediate 25 (6.0 g, 16.8 mmol) in 1,4-dioxane (60 mL) and water (12 mL) was added thiourea (2.56 g, 33.7 mmol) and Et3N (4.6 mL), and the mixture was stirred at 90°C for 3 h. The reaction was evaporated to dryness, water (20 mL) was added, extracted with AcOEt (3 x 30 mL), and dried over Na2SO4. Purification: flash chromatography on silica gel (DCM: MeOH = 100: 1) gave the title intermediate as a yellow solid (2.5 g).
[0370] 1 H-NMR (300MHz, CDCl3) δppm 7.20(s,1H),7.06-7.05(m,2H),6.74(s,1H),6.55(s,1H),4.87(bs,1H),2.87-2.84(m,4H),2.23(s,3H),1.53(s,9H).
[0371] ESI+m / z 334[M+H]
[0372] Embodiment 17
[0373] Preparation of intermediate 27
[0374] Methyl 4-(1-(ethylamino)cyclopropyl)benzoate
[0375]
[0376] A solution of methyl 4-(1-aminocyclopropyl)benzoate hydrochloride (1 g, 4.39 mmol; prepared as described in WO2008104055) and acetic acid (1.257 ml, 21.96 mmol) in DCE (30 ml) was stirred for 30 min, then sodium triacetoxyborohydride (1.396 g, 6.59 mmol) was added and the resulting mixture was stirred at RT overnight.
[0377] The reaction was treated with saturated NaHCO and extracted with DCM (300 ml). The organic layer was washed with water, dried and concentrated. The residue was purified by reverse phase chromatography (50 g, water / 0.1% AcOH to CH3CN / 0.1% AcOH) to give the title compound as a pale yellow oil (0.8 g).
[0378] 1 H NMR (400MHz, DMSO-d6) δppm 7.87(1H,d),7.43(1H,d),3.84(3H,s),2.44(2H,q),0.91-1.05(7H,m).
[0379] ESI+m / z 220[M+H]
[0380] Embodiment 18
[0381] Preparation of intermediate 28
[0382] 4-(1-(Ethylamino)cyclopropyl)benzoic acid
[0383]
[0384] To a solution of intermediate 27 (0.8 g, 3.65 mmol) in dioxane (10 ml) was added lithium hydroxide hydrate (0.184 g, 4.38 mmol) dissolved in water (10 ml). After 1 hour at RT, the reaction was concentrated, the residue was acidified with acetic acid (0.47 ml, 8.21 mmol) and purified by reverse phase chromatography (50 g, water / AcOH 0.1% to ACN / AcOH 0.1%). Yield 235 mg (white solid).
[0385] 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.91 (2H, d), 7.38 (2H, d), 2.14 (6H, s), 0.89 (2H, d), 0.78 (2H, d).
[0386] ESI+m / z 206[M+H]
[0387] Embodiment 19
[0388] Preparation of intermediate 29
[0389] 4-(Cyclopropylsulfonyl)picolinic acid
[0390]
[0391] A solution of a mixture of methyl 4-chloropicolinate (536 mg, 3.12 mmol), sodium cyclopropanesulfinate (400 mg, 3.12 mmol), quinoline (40.3 mg, 0.312 mmol) and copper (I) chloride (30.9 mg, 0.312 mmol) in NMP (5.5 ml) was heated at 150° C. for 1.5 h. Sodium cyclopropanesulfinate (50 mg, 0.390 mmol) was added and the reaction mixture was stirred at 150° C. for 12 hours. The reactants were acidified and loaded onto a reverse phase column (50 g) and eluted with H2O-AcOH (0.1%) / CH3CN-AcOH (0.1%). The residue was dissolved in water / EtOH and hydrated lithium (131 mg, 3.12 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours.
[0392] The ethanol was evaporated and the crude product was loaded onto a reverse phase column (50 g) and eluted with H2O-AcOH (0.1%) / CH3CN-AcOH (0.1%). Yield: 300 mg of off-white solid.
[0393] 1 H NMR(400MHz,DMSO-d6)δppm 14.01-13.45(m,1H),9.09-9.01(m,1H),8.41-8.34(m,1H),8.16-8.09(m,1H),3.17-3.07(m,1H),1.27-1.09(m,J=4.4Hz,4H).
[0394] ESI+m / z 228[M+H]
[0395] Embodiment 20
[0396] Preparation of intermediate 30
[0397] 2-(4-Methylpyridin-2-yl)propan-2-ol
[0398]
[0399] In a 2-necked flask, under a dry N2 atmosphere, 1-(4-methylpyridin-2-yl)ethanone (1.9 g, 14.06 mmol) was dissolved in THF (40 ml). The flask was cooled in an ice bath, and a solution of MeMgBr in tert-butyl ether (45 ml, 45.0 mmol) was added dropwise thereto. The solution was heated to 40 ° C and stirred for 3 hours. The reaction mixture was then cooled in an ice bath, quenched with a saturated NH4Cl aqueous solution (100 ml), and then extracted with ether (5 x 40 ml); the organic matter was washed with a saturated NaCl aqueous solution, dried with anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (50 g), eluting with 9 / 1 cyclohexane / AcOEt to 7 / 3 cyclohexane / AcOEt. Produced 1.09 g (light yellow oil).
[0400] 1 H NMR (400MHz, CDCl3) δppm 8.37(1H,d),7.19(1H,d),6.97-7.07(1H,m),5.12(1H,br.s.),2.39(3H,s),1.54(6H,s).
[0401] ESI+m / z 152[M+H]
[0402] Embodiment 21
[0403] Preparation of intermediate 31
[0404] 2-(2-Hydroxyprop-2-yl)isonicotinic acid
[0405]
[0406] At 60°C, a solution of intermediate 30 (500 mg, 3.31 mmol) in water (15 ml) was treated with KMnO4 (12 mmol). The reaction was heated to reflux for 20 h. The suspension was cooled to room temperature and then filtered through celite. The pH was adjusted to 2 by adding 1N HCl and the aqueous phase was washed with AcOEt. Solid NaHCO3 was added to neutralize the aqueous layer, concentrated to a minimum volume, acidified with AcOH, loaded onto a reverse phase column (50 g), eluted with water + 0.1% AcOH to acetonitrile + 0.1% AcOH only. Produced 322 mg (white solid).
[0407] 1 H NMR (400MHz, DMSO-d6) δppm 8.51(1H,d),8.07(1H,s),7.57(1H,d),4.95-5.57(1H,m),1.44(6H,s).
[0408] ESI+m / z 182[M+H]
[0409] Embodiment 22
[0410] Preparation of intermediate 32
[0411] 3-(N,N-Dimethylsulfamoyl)benzoic acid
[0412]
[0413] To a solution of 3-(chlorosulfonyl)benzoic acid (500 mg, 2.26 mmol) in THF (6 ml) was added dimethylamine (5.6 mL, 11.3 mmol) under nitrogen. The resulting mixture was stirred overnight at RT. The reaction solvent was then removed, AcOH (0.5 mL) and water (5 mL) were added, the resulting white solid was filtered, and dried under vacuum at 50 ° C for 5 h to give 3-(N,N-dimethylsulfamoyl)benzoic acid (420 mg).
[0414] 1 H NMR (400MHz, DMSO-d6) δppm 13.51 (1H, s), 8.25 (1H, d, J = 7.83Hz), 8.21 (1H, s), 7.97-8.03 (1H, m), 7.78-7.84 (1H, m), 2.65 (6H, s).
[0415] ESI+m / z 230[M+H]
[0416] Embodiment 23
[0417] Preparation of intermediate 33
[0418] 3-(Isopropylsulfonyl)benzoic acid
[0419]
[0420] To a solution of 3-sulfinylbenzoic acid (500 mg, 2.69 mmol) and potassium carbonate (1113 mg, 8.06 mmol) in DMF (10 ml) was slowly added 2-iodopropane (1.611 ml, 16.1 mmol) The reaction was stirred at RT for 3 days under nitrogen.
[0421] To hydrolyze the intermediate ester, NaOH (400 mg, 10 mmol) was added and the mixture was stirred overnight at RT. The reaction solvent was removed. DMSO (0.5 ml) and AcOH (0.8 mL) were then added to the remaining residue. The resulting solution was loaded onto a reverse phase column (50 g; 12 CV, only water + 0.1% AcOH to ACN + 0.1% AcOH). 290 mg (light yellow solid) was produced.
[0422] 1 H NMR (400 MHz, methanol-d4) δ ppm 8.49 (1H, t, J = 1.71 Hz), 8.34-8.41 (1H, m), 8.12 (1H, d, J = 7.83 Hz), 7.79 (1H, s), 3.35-3.45 (1H, m), 1.29 (6H, d, J = 6.85 Hz).
[0423] ESI+m / z 227[MH]
[0424] Embodiment 24
[0425] Preparation of intermediate 34
[0426] 1-(6-Chloro-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)ethan-1-one
[0427]
[0428] Acetyl chloride (0.345ml, 4.85mmol) was added to a cooled (0°C) solution of 6-chloro-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine (500mg, 3.23mmol, as prepared in WO2006082001) and DIPEA (0.847ml, 4.85mmol) in DCM (50ml). The resulting mixture was stirred at RT for 16 hours, then water was added and the phases were separated. The organic layer was concentrated and loaded onto a silica gel column (25g), which was eluted with a DCM / MeOH gradient from 10 / 0 to 9 / 1. The solvent was evaporated to give the title compound (538mg, off-white solid).
[0429] 1 H NMR (400MHz, DMSO-d6) δppm 8.41 (d, J = 2.4Hz, 1H), 7.56 (d, J = 1.0Hz, 1H), 4.86 (s, 2H), 4.63 (s, 2H), 2.06 (d, J = 3.4Hz, 3H).
[0430] ESI+m / z 197[MH]
[0431] Embodiment 25
[0432] Preparation of intermediate 35
[0433] 2-(2-Cyanoprop-2-yl)isonicotinic acid
[0434]
[0435] Prepared as described in WO2014151616.
[0436] Embodiment 26
[0437] Preparation of intermediate 36
[0438] 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborol-2-yl)-1H-pyrazol-1-yl)ethan-1-ol
[0439]
[0440] To 4-(4,4,5,5-tetramethyl-1,3,2- dioxaborane To a solution of 1-(2-yl)-1H-pyrazole (1 g, 5.15 mmol) in dry DMF (5 ml) was added solid K2CO3 (2.137 g, 15.46 mmol) followed by 2-bromoethanol (0.548 ml, 7.73 mmol). The resulting mixture was then heated to 80°C for 48 hours. DMF was evaporated and DCM (20 ml) was added to the remaining residue; the resulting mixture was then filtered to remove solids and evaporated to give a brown oil. Purification: Silica gel column (25 g) eluted with 1:1 cHex / AcOEt to 100% AcOEt. Produced 150 mg (light yellow oil).
[0441] 1 H NMR (400MHz, DMSO-d6) δppm 7.89(1H,s),7.57(1H,s),4.84(1H,t),4.15(2H,t),3.72(2H,q),1.25(12H,s).
[0442] ESI+m / z 239[M+H]
[0443] Embodiment 27
[0444] Preparation of intermediate 37
[0445] Ethyl 4-((1-benzhydrylazetidin-3-yl)oxy)benzoate
[0446]
[0447] A solution of 1-benzhydrylazetidine-3-ol (2.5 g, 10.45 mmol), ethyl 4-hydroxybenzoate (1.736 g, 10.45 mmol) and triphenylphosphine (2.74 g, 10.45 mmol) in acetonitrile (50 ml) was treated with (E)-diazene-1,2-diethyl dicarboxylate (4.76 ml, 10.45 mmol) and refluxed for 2 hours. The reaction mixture was then concentrated, and the resulting residue was dissolved in DCM, washed with water and concentrated. The residue was purified by silica gel chromatography (100 g, cyHex to 1 / 1 cyHex / AcOEt) to give the title compound (4 g; colorless oil).
[0448] 1 H NMR(400MHz,DMSO-d6)δppm 7.82-7.90(2H,m),7.41-7.48(4H,m),7.25-7.33(4H,m),7.16-7.23(2H,m),6.89-6.97(2H,m ),4.93(1H,t),4.53(1H,s),4.26(2H,q),3.61-3.70(2H,m),2.96-3.06(2H,m),1.29(3H,t).
[0449] ESI+m / z 388[M+H]
[0450] Embodiment 28
[0451] Preparation of intermediate 38
[0452] Ethyl 4-(azetidin-3-yloxy)benzoate
[0453]
[0454] To a solution of ethyl 4-((1-benzhydrylazetidin-3-yl)oxy)benzoate (2 g, 5.16 mmol) in 1,2-dichloroethane (25 ml) was added ACE-Cl (0.845 ml, 7.74 mmol), and the reaction mixture was stirred at 70° C. for 2 h. After cooling to room temperature, ethanol (25 ml) was added, and the reaction mixture was stirred at 70° C. for 36 h.
[0455] The reaction mixture was concentrated and loaded onto an SCX column (10 g), eluting with MeOH (3 CV) and 2.0 NH3 in MeOH (2 CV). The ammonia component was evaporated and purified by chromatography (55 g NH-KP, CH to AcOEt) to give 640 mg of the title compound (colorless oil).
[0456] ESI+m / z 222[M+H]
[0457] Embodiment 29
[0458] Preparation of intermediate 39
[0459] Ethyl 4-((1-isopropylazetidin-3-yl)oxy)benzoate
[0460]
[0461] Acetone (0.637 ml, 8.68 mmol) was added to a solution of ethyl 4-(azetidin-3-yloxy)benzoate (640 mg, 2.89 mmol) in acetic acid (15 ml, 262 mmol). The reaction mixture was stirred at room temperature for 10 min, and then sodium cyanotrihydroxyborate (582 mg, 9.26 mmol) was added. The reaction mixture was stirred at room temperature for 5 hours. The solvent was evaporated to give a crude product, which was loaded on a SNAP-C18 gold (150 g) column and eluted with H2O-AcOH (0.1%) / CH3CN-AcOH (0.1%). Produced 750 mg (light yellow oil).
[0462] ESI+m / z 264[M+H]
[0463] Embodiment 30
[0464] Preparation of intermediate 40
[0465] 4-((1-Isopropylazetidin-3-yl)oxy)benzoic acid
[0466]
[0467] Intermediate 39 (750mg, 2.85mmol) is dissolved in MeOH (15ml), and 2N sodium hydroxide (7.120ml, 14.24mmol) is added. The reactant is stirred for 16h. The reactant is concentrated, the residue is acidified with acetic acid, and then loaded onto a Phenomenex Strata SCX 20g post filled with MeOH. The chromatographic column is then eluted with MeOH, and then eluted with ammonia / MeOH. The components containing the desired product are combined and evaporated to obtain the title compound (380mg; white solid).
[0468] 1 H NMR (400MHz, DMSO-d6) δppm 7.79-7.95(2H,m),6.87-6.96(2H,m),4.81(1H,t),3.66-3.76(2H,m),2.90-3.02(2H,m),2.34(1H,quin),0.88(6H,d).
[0469] ESI+m / z 236[M+H]
[0470] Embodiment 31
[0471] Preparation of intermediate 41
[0472] 2-(6-Chloro-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)ethan-1-ol
[0473]
[0474] To a solution of 2-chloro-4,5-bis(chloromethyl)pyridine (500 mg, 2.375 mmol, prepared as in WO2006082001) in dry DMF (50 milliliters) was added N-ethyl-N-isopropyl-2-amine (1.655 ml, 9.50 mmol), followed immediately by solid 2-aminoethanol (0.143 ml, 2.375 mmol). The resulting mixture was then heated to 100° C. under nitrogen for 18 hours. The DMF in the reaction was then removed, DMSO (1 ml) was added to the remaining residue, and purified on a reverse phase column (50 g; 12 CV, only water + 0.1% AcOH to ACN + 0.1% AcOH). 330 mg of the title compound was produced (light brown oil).
[0475] 1 H NMR (400MHz, DMSO-d6) δppm 8.28 (1H, s), 7.44 (1H, s), 4.54 (1H, s), 3.91 (4H, s), 3.56 (2H, d, J = 5.38Hz), 2.70-2.81 (2H, m).
[0476] ESI+m / z 199[M+H]
[0477] Embodiment 32
[0478] Preparation of intermediate 42
[0479] 4-((Dimethylamino)methyl)benzoyl chloride
[0480]
[0481] To a solution of 4-((dimethylamino)methyl)benzoic acid (0.730 g, 4.07 mmol) in dry DCM (30 ml) was added oxalyl chloride (3.45 ml, 40.7 mmol) followed by N,N-dimethylformamide (0.016 ml, 0.204 mmol). The resulting mixture was stirred at 45°C overnight and then evaporated. A small sample was treated with MeOH and analyzed by mass spectrometry.
[0482] ESI+m / z 194 [M+H] (methyl ester).
[0483] Embodiment 33
[0484] Preparation of Intermediate (VI) (Intermediates 43-63) of Scheme 1
[0485] General Procedure 5
[0486] To a solution of Intermediate V (Intermediate 10-14) (1 mmol) in dioxane (10 ml) was added cesium carbonate (2 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.05 mmol) and tris(dibenzylideneacetone)dipalladium(0) (0.0175 mmol). The resulting mixture was then degassed in vacuo before the corresponding halogenated heterocycle R2X (1.05 mmol) was added. The reaction was heated at 90 °C for 3 hours, cooled and evaporated. AcOEt (25 mL) and DCM (25 mL) were added to the residue and the resulting mixture was then filtered through celite. The filtrate was then evaporated to give a brown residue which was purified on a silica gel column (25 g) eluting with DCM to 1:1 DCM / AcOEt to give the title intermediate.
[0487] General Procedure 6
[0488] To a dry DMSO (4 ml) solution of intermediate V (intermediate 10-14) (1 mmol) was added the corresponding halogenated heterocycle R2X (1.05 mmol), followed by N-ethyl-N-isopropylpropane-2-amine (2 mmol). The resulting mixture was stirred at 70 ° C for 2-4 h. The mixture was then added dropwise to water (50 mL) and extracted with DCM. The organic phase was washed with water, dried, and evaporated under reduced pressure to give a residue, which was purified on a silica gel column (25 g) eluted with 1:1 DCM to DCM / AcOEt to give the title intermediate.
[0489] General Procedure 7
[0490] Carboxylic acid R2COOH (1 mmol) was dissolved in toluene (5 ml), thionyl chloride (80 mmol) was added, and the mixture was stirred under reflux for 2 h.
[0491] The solvent was evaporated and the residue was added to a solution of intermediate V (intermediate 10-14) (1mmol) in pyridine (75mmol). The reaction was stirred at room temperature for 13h and then added to a mixture of water / DCM (20 / 20ml). The phases were separated and the aqueous layer was extracted with DCM (2x20ml). The combined organic layers were evaporated and the crude product was purified on a silica gel column (25g) and eluted with 1:1 cyclohexane / AcOEt to 100% AcOEt to obtain the title intermediate.
[0492] Table 5
[0493] Intermediates 43-63: Intermediates (VI) of Scheme 1
[0494]
[0495]
[0496]
[0497]
[0498] Embodiment 34:
[0499] Preparation of Intermediate (VII) (Intermediate 64-84) of Scheme 1
[0500] General Procedure 8
[0501] To a solution of intermediate 43-63 (1 mmol) in DCM (10 ml) was slowly added TFA (5 ml). After 3 hours at RT, the reaction was stripped of volatiles under vacuum, DCM (40 ml) and saturated aqueous sodium bicarbonate solution (75 ml) were added; the organic phase was separated, dried over anhydrous sodium sulfate and evaporated to give the title intermediate.
[0502] Table 6
[0503] Intermediates 64-84: Intermediates (VII) of Scheme 1
[0504]
[0505]
[0506]
[0507]
[0508] Embodiment 35:
[0509] Preparation of Intermediate (VIII) (Intermediate 85-111) of Scheme 1
[0510] General Procedure 9
[0511] To a solution of intermediate (VII) (Intermediates 65; 66; 67; 71; 72; 75; 76; 77; 80; 81; 82; 83; 84) (1 mmol) in pyridine (24 mmol) was added the acid chloride (1.5 mmol) and the resulting mixture was stirred at RT for 1-4 hours.
[0512] The solvent was evaporated and the residue was purified by reverse phase column (50 g) with a gradient elution of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%). The fractions containing the desired product were loaded onto a Strata-XL-C 100 μm SPE (2 g) column and eluted with H2O / MeOH and 1M NH3 in MeOH. The ammonia component was evaporated to give the title intermediate.
[0513] General Procedure 10
[0514] Under nitrogen, carboxylic acid (1.5 mmol), HOBT (1.5 mmol), EDC (1.5 mmol) and DIPEA (3 mmol) were dissolved in DMF (10 ml). After activation for 15 minutes, the mixture was added to a solution of intermediate (VII) (Intermediate 65; 66; 67; 71; 72; 75; 76; 77; 80; 81; 82; 83; 84) (1 mmol) in DMF (7.5 ml). The resulting mixture was stirred at room temperature for 5-7 h. The solvent was evaporated and the residue was purified by reverse phase chromatography (50 g) with a gradient elution of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%).
[0515] Fractions containing the desired product were loaded onto a Strata-XL-C 100 μm SPE (2 g) column and eluted with H2O / MeOH and 1 M NH3 in MeOH. The ammonia fraction was evaporated to give the title intermediate.
[0516] General Procedure 11
[0517] To a solution of intermediate (VII) (Intermediate 65; 66; 67; 71; 72; 75; 76; 77; 80; 81; 82; 83; 84) (1 mmol) in DMF (8 ml) was added CDI (2 mmol). After 3 hours, an amine (4 mmol) was added and the resulting mixture was stirred at 50° C. for 1 h and then loaded onto a reverse phase column (50 g) and eluted with water + 0.1% AcOH only to acetonitrile + 0.1% AcOH only to give the title intermediate.
[0518] Table 7 Intermediate 85-111: Intermediate (VIII) of Scheme 1
[0519]
[0520]
[0521]
[0522]
[0523]
[0524] Embodiment 36
[0525] Preparation of intermediate 112
[0526] 6-((5-(2-fluoro-5-(3-(trifluoromethyl)benzamido)phenethyl)-1H-pyrazol-3-yl)amino)-2-methyl Methyl pyrimidine-4-carboxylate
[0527]
[0528] 3-(Trifluoromethyl)benzoyl chloride (0.098 ml, 0.648 mmol) was added to a solution of intermediate 72 (160 mg, 0.432 mmol) in pyridine (1 ml, 12.36 mmol) and the resulting mixture was stirred for 1 h. The solvent was evaporated, the residue was dissolved in MeOH and NaOMe (100 mg) was added. The mixture was stirred at RT overnight.
[0529] The solvent was evaporated and the residue was partitioned between AcOEt and dilute HCl. The separated organic phase was concentrated and the residue was purified by silica gel column (25 g) eluting with 100% cyclohexane to 100% AcOEt to give the title intermediate (155 mg; yellow solid).
[0530] ESI+m / z 543[M+H]
[0531] Embodiment 37
[0532] Preparation of intermediate 113
[0533] N-(4-Fluoro-3-(2-(3-((6-(hydroxymethyl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl) phenyl)-3-(trifluoromethyl)benzamide
[0534]
[0535] To a solution of intermediate 112 (155 mg, 0.286 mmol) in THF (3 ml) was added a solution of LiBH4 in THF (0.179 ml, 0.714 mmol) and the mixture was stirred at RT for 1 h.
[0536] AcOH was added and the solution was evaporated. The residue was dissolved in AcOH (2 ml) and evaporated again. The residue was purified by reverse phase chromatography (50 g; 0.1% water / AcOH to 0.1% ACN / AcOH). The relevant components were collected and concentrated, basified with 1N NaOH, extracted with AcOEt, washed with brine, dried and concentrated to give the title intermediate (70 mg; white solid).
[0537] 1 H NMR(400MHz,DMSO-d6)δppm 12.08(1H,br.s.),10.47(1H,s),9.57(1H,br.s),8.20-8.36(2H,m),7.98(1H,d),7.71-7.84(2H,m),7.59- 7.71(1H,m),7.19(2H,m),6.17(1H,br.s),5.23-5.40(1H,m),4.33(2H,d),2.83-3.03(4H,m),2.37(3H,s).
[0538] ESI+m / z 515[M+H]
[0539] Embodiment 38
[0540] Preparation of intermediate 114
[0541] (6-((5-(2-fluoro-5-(3-(trifluoromethyl)benzamido)phenethyl)-1H-pyrazol-3-yl)amino)-2- 4-Methylpyrimidin-4-yl)methyl methanesulfonate
[0542]
[0543] To a solution of intermediate 113 (70 mg, 0.136 mmol) and N,N-diethylethanamine (0.038 ml, 0.272 mmol) in THF (6 ml) was added methanesulfonyl chloride (0.016 ml, 0.204 mmol) at 0° C., and the resulting mixture was stirred at RT for 3 h. The solution was used directly in the subsequent reaction (see Example 46, compounds 26, 27 and 28).
[0544] Embodiment 39
[0545] Preparation of intermediate 115
[0546] N-(3-(2-(5-((6-chloro-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-fluorophenyl)- 3-(Trifluoromethyl)benzamide
[0547]
[0548] 3-(Trifluoromethyl)benzoyl chloride (0.098ml, 0.648mmol) was added to a solution of intermediate 78 (150mg, 0.433mmol) in pyridine (1ml, 12.36mmol), and the resulting mixture was stirred for 1h. The solvent was evaporated, the residue was dissolved in MeOH, and NaOMe (100mg) was added. The mixture was stirred overnight at RT. The solvent was evaporated, and the residue was distributed between AcOEt and dilute HCl. The organic phase separated was concentrated, and the residue was purified by silica gel column (25g), eluted with 100% cyclohexane to 100% AcOEt to obtain the title intermediate (165mg; yellow solid).
[0549] 1 H NMR(400MHz,DMSO-d6)δppm 12.21(1H,br.s.),10.46(1H,s),10.07(1H,s),8.19-8.34(2H,m),7.98(1H,d),7 .59-7.86(3H,m),7.19(1H,t),6.07(1H,br.s.),2.83-3.01(4H,m),2.40(3H,s).
[0550] ESI+m / z 519[M+H]
[0551] Embodiment 40:
[0552] Preparation of Intermediate (X) (Intermediate 116) of Scheme 2
[0553] N-(5-(2-(5-amino-1-(tert-butyl)-1H-pyrazol-3-yl)ethyl)-2-fluorophenyl)-3-(trifluoromethyl) Benzamide
[0554]
[0555] To intermediate 16 (500 mg, 1.470 mmol), 3-(trifluoromethyl)benzamide (834 mg, 4.41 mmol), tripotassium phosphate (936 mg, 4.41 mmol), tetramethyldi-tBuXPhos (70.6 mg, 0.147 mmol), tris(dibenzylideneacetone)palladium(0) (60.6 mg, 0.066 mmol) was added dry dioxane (10 ml) under nitrogen. The resulting mixture was heated to 105°C and left at this temperature overnight. The reaction was cooled to RT and the dioxane was then removed under vacuum. DCM (15 ml) and water (20 ml) were added to the remaining residue. After brief mixing, the organic layer was separated, dried over anhydrous sodium sulfate, and then evaporated to a brown residue. Purification: Silica gel column (25 g) eluted with DCM to 1:1 DCM / AcOEt to give the title intermediate (597 mg; brown solid).
[0556] 1 H NMR(400MHz,DMSO-d6)δppm 10.34(1H,s),8.24-8.35(2H,m),7.99(1H,d),7.73-7.85(1H,m),7.48(1H,dd),7.08-7. 23(2H,m),5.25(1H,s),4.72(2H,s),2.77-2.87(2H,m),2.57-2.66(2H,m),1.49(9H,s).
[0557] ESI+m / z 449[M+H]
[0558] Embodiment 41:
[0559] Preparation of Intermediate (XI) (Intermediate 117) of Scheme 2
[0560] N-(5-(2-(5-amino-1-(tert-butyl)-1H-pyrazol-3-yl)ethyl)-2-fluorophenyl)-3-(trifluoromethyl) Benzamide
[0561]
[0562] To intermediate 116 (590 mg, 1.316 mmol) was added formic acid (24.8 ml, 658 mmol). The resulting solution was heated to 100 °C for 24 hours. The volatiles in the reaction were then stripped and the remaining residue was dissolved in DMSO (2 ml) and purified by reverse phase chromatography (50 g; 0.1% water / AcOH to 0.1% ACN / AcOH). Yield: 495 mg; yellow solid.
[0563] 1 H NMR(400MHz,DMSO-d6)δppm 11.11(1H,br.s.),10.36(1H,s),8.22-8.37(2H,m),7.99(1H,d),7.73-7.86(1H,m),7 .48(1H,dd),7.08-7.27(2H,m),5.21(1H,br.s.),4.41(2H,br.s.),2.64-2.92(4H,m).
[0564] ESI+m / z 393[M+H]
[0565] Embodiment 42:
[0566] Preparation of intermediate 118
[0567] N-(5-(2-(5-((6-chloro-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)-2-fluorophenyl)- 3-(Trifluoromethyl)benzamide
[0568]
[0569] To a solution of intermediate 117 (150 mg, 0.382 mmol) in dry DMSO (2 mL) was added solid 4,6-dichloro-2-methylpyrimidine (68.6 mg, 0.421 mmol) followed by N-ethyl-N-isopropylpropan-2-amine (0.200 mL, 1.147 mmol). The resulting mixture was stirred at 60 °C for 24 hours. The volatiles in the reaction were then stripped and the remaining residue was dissolved in acetic acid (0.3 ml) and purified by reverse phase chromatography (50 g; 0.1% water / AcOH to 0.1% ACN / AcOH). Yield: 158 mg; yellow solid.
[0570] 1 H NMR(400MHz,DMSO-d6)δppm 12.17(1H,br.s.),10.36(1H,s),10.07(1H,s),8.19-8.36(2H,m),7.99(1H,d),7.80(1H ,t),7.52(1H,dd),7.10-7.31(2H,m),5.74-6.32(1H,m),2.82-3.00(4H,m),2.41(3H,s).
[0571] ESI+m / z 519[M+H]
[0572] Embodiment 43:
[0573] Preparation of Intermediate (XIII) (Intermediate 119) of Scheme 3
[0574] 3-(3-aminobenzyl)-1-(tert-butyl)-1H-pyrazol-5-amine
[0575]
[0576] To monoiodocopper (0.259 g, 1.358 mmol), (S)-pyrrolidine-2-carboxylic acid (0.313 g, 2.72 mmol) and potassium carbonate (2.252 g, 16.29 mmol) in a high pressure bottle, dry and degassed DMSO (8 ml) was added. The resulting purple mixture was stirred for 10 minutes. After 10 minutes, solid intermediate 18 (1.75 g, 5.43 mmol) was immediately added. The bottle was then sealed, and after sealing, 28% ammonia (4 ml, 59.0 mmol) was added. The resulting mixture was then heated to 100 ° C under microwave for 8 hours. The reactant was cooled to RT and then added dropwise in water / DCM (20 ml). After brief mixing, the organic layer was separated, dried over anhydrous sodium sulfate, and then evaporated to a dark blue oil. Purification: Silica gel column (55 g) eluted with 75:25 cHex / DCM, then through reverse phase column (150 g) eluted with 0.1% water / AcOH to 0.1% ACN / AcOH. Produced 1.178 g of the title intermediate as an off-white solid.
[0577] 1 H NMR(400MHz,DMSO-d6)δppm 6.90(1H,t),6.45(1H,t),6.30-6.42(2H,m),5.23(1H,s),4.89(2H,br.s.),4.70(2H,s),2.59-2.67(2H,m),2.53-2.58(2H,m),1.50(9H,s).
[0578] ESI+m / z 259[M+H]
[0579] Embodiment 44:
[0580] Preparation of Intermediate (XIV) (Intermediate 120) of Scheme 3
[0581] N-(3-(2-(5-amino-1-(tert-butyl)-1H-pyrazol-3-yl)ethyl)phenyl)-4-((dimethylamino)methyl Benzamide
[0582]
[0583] To a dry DCM (4ml) solution of intermediate 119 (150mg, 0.581mmol) was added dry pyridine (0.235ml, 2.90mmol). To the resulting solution was added intermediate 42 (163mg, 0.697mmol). After the addition was complete, the reactant was stirred overnight at RT. Saturated sodium bicarbonate aqueous solution was then added to the reactant. After brief mixing, the organic layer was separated, dried over anhydrous sodium sulfate, and then evaporated to a brown oil. Purification: silica gel column (25g), eluted with 1:1 cHex / AcOEt to AcOEt. Produced 185mg (yellow solid).
[0584] 1 H NMR(400MHz,DMSO-d6)δppm 10.12(1H,s),7.93(2H,d),7.68(1H,s),7.62(1H,d),7.45(2H,d),7.24(1H,t),6.98(1H,d),5.25 (1H,s),4.72(2H,s),3.51(2H,br.s.),2.80(2H,dd),2.59-2.66(2H,m),2.20(6H,s),1.50(9H,s).
[0585] ESI+m / z 420[M+H]
[0586] Embodiment 45:
[0587] Preparation of Intermediate (XV) (Intermediate 121) of Scheme 3
[0588] N-(1-(tert-butyl)-3-(3-(4-((dimethylamino)methyl)benzamido)phenethyl)-1H-pyrazole-5-yl 4-Morpholinylbenzamide
[0589]
[0590] To a solution of intermediate 120 (80 mg, 0.191 mmol) in dry DCM (4 ml) was added pyridine (0.077 ml, 0.953 mmol) followed by 4-morpholinobenzoyl chloride (86 mg, 0.381 mmol). The resulting mixture was stirred overnight. Saturated aqueous sodium bicarbonate solution (2 ml) and water (2 ml) were added to the reaction; the organic layer was separated, dried over anhydrous sodium sulfate, and evaporated to a dark brown residue. Purification: reverse phase column (150 g), eluted with 0.1% water / AcOH to 0.1% ACN / AcOH. Yield 140 mg (light brown oil).
[0591] ESI+m / z 609[M+H]
[0592] Embodiment 46:
[0593] Preparation of Intermediate (XVII) (Intermediate 122) of Scheme 4
[0594] tert-Butyl (4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)carbamate
[0595]
[0596] To an oven dried microwave tube equipped with a magnetic stirrer was added 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.038 g, 0.066 mmol) and tris(dibenzylideneacetone)dipalladium(0) (0.018 g, 0.020 mmol), intermediate 26 (0.22 g, 0.660 mmol) and 2-bromopyrazine (0.066 ml, 0.726 mmol). The vessel was evacuated and backfilled with nitrogen (three times). Dioxane (5 ml) was added to the vessel, evacuated and backfilled with nitrogen. The reaction was heated at 95°C overnight, then cooled to room temperature, the volatiles were evaporated and the crude product was dissolved in DMSO (3 ml) and AcOH (2 ml). Purification: reverse phase column (50 g), eluted with 0.1% water / AcOH to 0.1% ACN / AcOH. Produced 262 mg of the title intermediate (yellow solid).
[0597] 1 H NMR(400MHz,DMSO-d6)δppm 11.41-11.63(1H,m),9.13(1H,s),8.45(1H,s),8.28(1H,dd),8.09(1H,d),7.79(1H,s),7.43-7.53(1 H,m),7.27-7.43(3H,m),7.11-7.21(2H,m),7.02(1H,d),2.78-3.01(4H,m),2.21(3H,s),1.46(9H,s).
[0598] ESI+m / z 412[M+H]
[0599] Embodiment 47:
[0600] Preparation of Intermediate (XVIII) (Intermediate 123) of Scheme 4
[0601] 5-(5-amino-2-methylphenethyl)-N-(pyrazin-2-yl)thiazol-2-amine
[0602]
[0603] At RT, to a solution of intermediate 122 (369 mg, 0.897 mmol) in DCM (5 ml) was slowly added TFA (0.691 ml, 8.97 mmol), and the reaction was stirred at RT for 2 hours. The volatiles were evaporated and the crude product was loaded onto SPE-SCX (5 g). The basic component was collected and evaporated to give the title intermediate (196 mg; yellow solid).
[0604] 1H NMR(400MHz,DMSO-d6)δppm 11.38-11.59(1H,m),8.42-8.51(1H,m),8.22-8.33(1H,m),8.03-8.16(1H,m),7.16(1H,s),6.71-6.85( 1H,m),6.44(1H,d),6.34(1H,dd),4.68-4.91(2H,m),2.86-2.98(2H,m),2.74(2H,br.s.),2.12(3H,s).
[0605] ESI+m / z 312[M+H]
[0606] Embodiment 48
[0607] Scheme 1 is a general procedure for preparing compounds of the present invention (Formula I):
[0608] General Procedure 12:
[0609] Intermediate 85-111 (1 mmol) was dissolved in formic acid (100 mmol). The resulting mixture was heated at 95 °C for 2 h. The solvent was evaporated and the residue was purified on a reverse phase column (25 g) eluting with 0.1% water / AcOH to 0.1% ACN / AcOH. The fractions containing the desired product were loaded onto a Strata-XL-C 100 μm SPE (2 g) column and eluted with H2O / MeOH and 1M NH3 in MeOH. The ammonia component was evaporated to give the title compound.
[0610] General Procedure 13:
[0611] Carboxylic acid (1.5 mmol), HOBT (1.5 mmol), EDC (1.5 mmol) and DIPEA (3 mmol) were dissolved in DMF (10 ml) under nitrogen. After activation for 15 minutes, the mixture was added to a solution of intermediate (VII) (intermediates 67; 68; 69; 77) in DMF (7.5 ml). The resulting mixture was stirred at RT for 5-7 h. The solvent was evaporated and the residue was purified by reverse phase chromatography (50 g) eluting with a gradient of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%).
[0612] Fractions containing the desired product were loaded onto a Strata-XL-C 100 μm SPE (2 g) column and eluted with H2O / MeOH and 1 M NH3 in MeOH. The ammonia fraction was evaporated to give the title compound.
[0613] General Procedure 14:
[0614] To a solution of intermediate 115 (0.1 mmol) in dry DMSO (3 ml) was added the corresponding amine (1 mmol). The resulting solution was then heated to 80°C for 5-8 hours, cooled to RT, acetic acid (0.5 ml) was added and the resulting mixture was purified by reverse phase chromatography (25 g) eluting with a gradient of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%).
[0615] General Procedure 15:
[0616] The THF solution containing intermediate 114 (see Example 38) was divided into 3 portions (each containing 0.045 mmol), and then the corresponding amine (0.18 mmol) was added. The resulting solution was then heated to 60°C overnight and evaporated; MeOH (5 ml) and MeONa (50 mg) were added, and the mixture was stirred at RT for 2 hours and then evaporated. Purification: reverse phase chromatography (15 g), eluting with a gradient of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%).
[0617] General Procedure 16:
[0618] To a solution of intermediate (VII) (intermediate 67) (1 mmol) in DMF (8 ml) was added CDI (2 mmol). After 3 hours, an amine (4 mmol) was added and the resulting mixture was stirred at 50°C for 1 h and then loaded onto a reverse phase column (50 g) and eluted with water + 0.1% AcOH only to acetonitrile + 0.1% AcOH only to give the title compound.
[0619] Refer to Table 8 below, according to the above program (column 3 in the table), starting from the intermediate prepared above (shown in column 2 in the table below), compound 1-41 was prepared:
[0620] Table 8
[0621] Compound 1-41
[0622]
[0623]
[0624]
[0625]
[0626]
[0627]
[0628]
[0629]
[0630]
[0631]
[0632] Embodiment 49:
[0633] Preparation of Compound (I) (Compound 42) of Scheme 1
[0634] N-(4-Fluoro-3-(2-(3-((6-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-2-methylpyrimidin-4-yl)amino 1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide
[0635]
[0636] To a solution of intermediate 115 (25 mg, 0.048 mmol) in THF (3.5 ml) was added intermediate 36 (28.7 mg, 0.120 mmol) followed by a solution of sodium carbonate (15.32 mg, 0.145 mmol) in water (1 ml). The resulting solution was degassed under vacuum and then placed under a nitrogen atmosphere. To this mixture was then added bis(triphenylphosphine)palladium(II) dichloride (6.76 mg, 9.64 μmol) and the reaction was then heated to 80°C for 2 hours and then evaporated. To the remaining residue was added water (0.5 ml), acetic acid (0.5 ml) and DMSO (1.5 ml). Purification: Reverse phase chromatography (25 g) with a gradient elution of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%). This gave 20 mg of the title compound (white solid).
[0637] 1 H NMR(400MHz,DMSO-d6)δppm 12.11(1H,br.s.),10.47(1H,s),9.57(1H,br.s.),8.16-8.34(3H,m),7.97(1H,d),7.87(1H,s),7.73-7.82(2H,m),7.63 -7.69(1H,m),7.19(2H,t),6.13(1H,br.s.),4.91(1H,br.s.),4.20(2H,t),3.76(2H,t),2.86-3.01(4H,m),2.42(3H,s).
[0638] ESI+m / z 595[M+H]
[0639] Embodiment 50
[0640] Scheme 2 is a general procedure for preparing compounds of the present invention (Formula I):
[0641] General Procedure 17:
[0642] To a solution of intermediate 118 (0.1 mmol) in dry DMSO (3 ml) was added the corresponding amine (1 mmol). The resulting solution was then heated to 80°C for 5-8 hours, cooled to RT, acetic acid (0.5 ml) was added and the resulting mixture was purified by reverse phase chromatography (25 g) eluting with a gradient of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%).
[0643] Refer to Table 9 below, according to the above program (column 3 in the table), starting from the intermediate prepared above (shown in column 2 in the table below), compounds 43-46 were prepared:
[0644] Table 9
[0645] Compounds 43-46
[0646]
[0647]
[0648] Embodiment 51:
[0649] Preparation of Compound (I) (Compound 47) of Scheme 3
[0650] 4-((Dimethylamino)methyl)-N-(3-(2-(5-(4-morpholinylbenzamido)-1H-pyrazol-3-yl)ethyl) Benzamide
[0651]
[0652] To intermediate 121 (80 mg; 0.191 mmol) was added formic acid (1.798 ml, 47.7 mmol) and the resulting solution was heated to 100° C. for 1 hour. The formic acid was removed under vacuum and DMSO (1 ml) and acetic acid (0.25 ml) were added to the remaining residue. Purification: Reverse phase chromatography (15 g) with a gradient elution of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%). Yield 28 mg (off-white solid).
[0653] 1H NMR(400MHz,DMSO-d6)δppm 12.14(1H,br.s.),10.37(1H,br.s.),10.16(1H,s),7.92(4H,dd),7.57-7.78(2H,m),7.44(2H,d),7.27(1H,t),6.8 8-7.06(3H,m),6.42(1H,br.s.),3.65-3.82(4H,m),3.47(2H,s),3.18-3.28(4H,m),2.81-3.01(4H,m),2.17(6H,s).
[0654] ESI+m / z 553[M+H]
[0655] Embodiment 52
[0656] Scheme 4: General procedure for preparing compounds of the present invention (Formula I):
[0657] General Procedure 18:
[0658] Under nitrogen, carboxylic acid (1.5 mmol), HOBT (1.5 mmol), EDC (1.5 mmol) and DIPEA (3 mmol) were dissolved in DMF (10 ml). After activation for 15 minutes, the mixture was added to a solution of intermediate (XVIII) (intermediate 123) in DMF (7.5 ml). The resulting mixture was stirred at RT for 5-7 h. The solvent was evaporated and the residue was purified by reverse phase chromatography (50 g) with a gradient elution of H2O-AcOH (0.1%) to CH3CN-AcOH (0.1%).
[0659] Refer to Table 10 below, according to the above program (column 3 in the table), starting from the intermediate prepared above (shown in column 2 in the table below), compounds 48-50 were prepared:
[0660] Table 10
[0661] Compounds 48-50
[0662]
[0663] Pharmacological evaluation of the compounds of the present invention
[0664] According to the present invention, a number of compounds of formula (I) have been studied in vitro to determine their potential Fyn kinase and VEGFR2 kinase inhibitory activity and their therapeutic efficacy in certain cell models, as well as to determine the efficacy of the best compounds obtained by in vitro screening in experiments on induced hyperalgesia and pain behavior in rats.
[0665] The following Tables 11-16 summarize the results obtained.
[0666] Example 53: In vitro kinase activity assay
[0667] The Fyn kinase inhibitory activity of representative examples of the compounds of formula (I) was evaluated using the Z'-LYTE kinase assay platform (Invitrogen). The compounds were evaluated for active Fyn (full-length activity, molecular weight 87.1 kD; Invitrogen). The enzyme (1.2 ng / μl) was mixed with synthetic peptide-substrate ATP (50 M) and different concentrations (ranging from 10 -9 M to 10 -5 The inhibitors were incubated in 384 small volume microplates with 1% DMSO (final concentration of 1% DMSO in reaction buffer 50 mM Hepes, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35, pH 7.5). The kinase reactions were carried out at 25°C for 60 minutes in a total volume of 10 μl. A 0% phosphorylation (i.e. no ATP) assay control and a 100% phosphorylation assay control were included in each plate to calculate the percentage of phosphorylation achieved in a particular reaction well. The results are expressed as percent inhibition and are plotted using GraphPad TM IC was calculated by nonlinear curve fitting using Prism software (Windows version 6). 50 value.
[0668] The Fyn kinase inhibitory activity of representative compounds of formula (I) is reported in Table 11 below.
[0669] Table 11: FYN kinase inhibition
[0670] Compound <![CDATA[IC 50 (nM)]]> Compound <![CDATA[IC 50 (nM)]]> Compound <![CDATA[IC 50 (nM) <!-- 59 -->]]> 1 36 18 15 35 88 2 10 19 69 36 32 3 9 20 18 37 24 4 21 21 5 38 2 5 6 22 7 39 1 6 112 23 5 40 99 7 63 24 2 41 8 8 20 25 3 42 13 9 16 26 12 43 19 10 4 27 10 44 8 11 21 28 17 45 22 12 24 29 15 46 18 13 26 30 6 47 10 14 31 31 10 48 27 15 18 32 9 49 143 16 24 33 16 50 8 17 8 34 6
[0671] result
[0672] As shown in Table 11, the compound of formula (I) is a potent Fyn kinase inhibitor with IC 50 The values were in the low to mid nanomolar range. Only compounds 6 and 49 were active in the high nanomolar range (>100 nM).
[0673] Example 54: In vitro kinase activity assay
[0674] The VEGFR2 kinase inhibitory activity of representative examples of compounds of formula (I) assay was evaluated in Eurofins Cerep (France). The inhibitor concentration range in the study was 10 -8 M to 10 -5 The final concentration is from 10 -9Some compounds were retested over a range of concentrations starting at M. Results are expressed as percentage of control activity (in the absence of test compound), and IC was determined by nonlinear regression analysis of inhibition / concentration curves generated using average replicate values. 50 value.
[0675] The VEGFR2 kinase inhibitory activity of representative compounds of Formula (I) is reported in Table 12 below.
[0676] Table 12: VEGFR2 Kinase Inhibition
[0677] Compound <![CDATA[IC 50 (nM)]]> Compound <![CDATA[IC 50 (nM)]]> Compound <![CDATA[IC 50 (nM)]]> 1 <10 18 16 42 20 2 <10 19 110 43 10 3 7 26 <10 44 <10 4 <10 27 12 45 <10 5 <10 28 <10 46 <10 6 <10 29 <10 47 10 7 <10 30 <10 48 10 8 <10 31 18 9 <10 32 <10 10 <10 33 <10 11 <10 34 <10 12 <10 35 <10 13 <10 36 <10 14 10 37 35 15 <10 39 11 16 <10 40 <10 17 <10 41 <10
[0678] result
[0679] As shown in Table 12, the compound of formula (I) is a good VEGFR2 kinase inhibitor (IC 50 <10 nM), compounds 1-17, 20-30, 32-36, 38, 40-48 are potent VEGFR2 kinase inhibitors.
[0680] Example 55: In vitro kinase activity analysis in the presence of high ATP concentrations
[0681] Inhibition of Fyn and VEGFR2 kinase activity was assessed at a fixed ATP concentration (0.5 mM) close to the millimolar range present in cells. The assay was powered by ADP-Glo TM Kinase assays (Promega) were performed to monitor ADP production during kinase reactions. Kinase reactions were performed in 10 μl white 384-well plates according to the supplier's instructions. Inhibitor solutions in DMSO / kinase buffer were preincubated with kinases (final concentrations of 2.5 ng / μl Fyn and 0.5 ng / μl VEGFR2 in the assay) for 15 min at room temperature. Inhibitor concentrations ranged from 10 -10 M to 10 -5 To start the reaction, add substrate / ATP mix (0.5 mM final concentration, corresponding to 10x ATP K M After incubation at room temperature for 60 minutes, ADP-Glo TM The inhibitory percentage calculated for enzyme activity in the absence of the test compound and the corresponding inhibition curve were analyzed by nonlinear curve fitting (GraphPad software, Windows version 7) to calculate the IC 50 value.
[0682] result
[0683] In the presence of high ATP concentrations, compound 3 inhibited Fyn and VEGFR2 in a concentration-dependent manner, with IC 50 The values were 6.8 nM and 58 nM, respectively.
[0684] Example 56: Kinase Selectivity
[0685] The kinase selectivity of some representative compounds of formula (I) was analyzed in a standard panel of 46 human kinases and it was determined that 10 kinases were affected more frequently. Therefore, the kinase selectivity of compound 3 against these 10 kinases was tested. The analysis was performed in EurofinsCerep (France). The concentration range of the compounds in the study was 10 -9 M to 10 -5 The final concentration of M. Table 13 summarizes the results.
[0686] Table 13: Kinase selectivity
[0687]
[0688] IN: Inactive at the maximum concentration tested (10 μM)
[0689] result
[0690] As shown in Table 12, compound 3 exhibited nanomolar potency in inhibiting Fyn and VEGFR2 kinase activity. In addition to the effects on other kinases of the Src family (Src, Yes, and Lyn-A) (but less than the effects on Fyn and VEGFR2), compound 3 was inactive (>1000 nM) against the other kinases studied.
[0691] Example 57: Cell Model for Testing Kinase Inhibition - Gene Reporter (GR) Assay
[0692] In order to determine whether the compounds of the invention are also active in a cell model, a gene reporter assay was established in a cell line (JB6 Cl 41-5a (P+)) known to activate Fyn kinase via inflammatory stimuli (TNFα). The GR assay measures the activation of the nuclear transcription factor NF-kB, which is located downstream of the Fyn activation pathway. Products that are active in this assay must penetrate into the cell and inhibit the NF-kB activation pathway.
[0693] The mouse epithelial cell line JB6Cl 41-5a (P+) was stably transfected with pGL4.32[luc2P / NFkB-RE / Hygro] vector (Promega) Catalog #CRL-2010). Clonal selectivity was achieved by restriction with 80 μg / ml hygromycin B. Clones were tested for response to TNFα stimulation.
[0694] JB6(P+)NFkB-RE-luc2P transfected cells were used to analyze the regulation of NF-kB activity by Fyn inhibitor after TNFα stimulation.
[0695] Cells were pretreated with different compounds for 1 h and then stimulated with 2 ng / ml TNFα for 4 h. Each test condition was analyzed in quadruplicate.
[0696] Using ONE-Glo TM +Tox Luciferase Reporter and Cell Viability Assay Kit (Promega) was used for luciferase analysis. TM Cell viability assays assessed the results obtained at non-toxic concentrations.
[0697] Table 14: Gene Reporter (GR) Suppression
[0698]
[0699] ne: no effect
[0700] result
[0701] As shown in Table 14, some compounds of the present invention were demonstrated to be able to penetrate cells and inhibit Fyn kinase activation induced by TNF-α stimulation at submicromolar / micromolar concentrations. In particular, compounds 3, 8 and 15 showed IC 50 Value <250nM.
[0702] Example 58: Intracellular target engagement of FYN enzyme in HEK 293 transfected cells
[0703] Intracellular target engagement (TE) of Fyn kinase was demonstrated using nanoBRET technology (Promega), which allows measurement of compound binding at selected target proteins within intact cells and expression of TE via nanoBRET. TM The apparent affinity of the test compound is determined by competitive displacement of a tracer that reversibly binds to the Luciferase fusion protein.
[0704] Using NanoBRET TM TE intracellular kinase assay K-4 (Promega, #N2520) was used to measure HEK293 cells transiently transfected with fusion vector (Promega, #NV1411) Catalog No. CRL-1573) and thus expresses the intracellular target of Fyn kinase Fusion protein. A final concentration of 0.33 M tracer was used and cells were treated with compound for 2 h. Discover, Promega) measured the luminescence value and determined the raw BRET ratio for each sample. Fusion of the compound will result in a decrease in BRET signal and a lower BRET ratio.
[0705] result
[0706] Compound 3 had an effect on transiently expressed WT cells in HEK293 cells. IC of fusion protein 50 The combined value is 1.5M.
[0707] Example 59: Inhibition of FYNB-induced TAU(Y18)-phosphorylation (cell-based assay)
[0708] HEK293 cells (human embryonic kidney 293) were cultured at 6×10 5 The cells were seeded in poly-D-lysine 12w microplates and grown in DMEM / 10% FBS at 5% CO2 and 37°C. 3000 transfection protocol (Life Technologies TM ), cells were transfected to overexpress constitutively active forms of human FynB and Tau protein (isoform 0N4R). Untransfected samples (negative controls) were included in each experiment. 24 hours after transfection, cells were treated by adding fresh culture medium containing diluent (final concentration of 0.1% DMSO) or test compounds. Incubate for 6 or 24 hours at 5% CO2 and 37°C. At the end of incubation, the culture medium was removed, and the cell lysate obtained by adding a mixture of M-PER cleavage / protease / phosphatase inhibitors was transferred to an Eppendorf tube, sonicated, and stored at -80°C. Protein content was measured by the Bradford method. Lysates were analyzed by a custom ELISA assay for Tau phosphorylation (tyrosine 18 residues-Fyn mediated) and a Tau-total assay.
[0709] result
[0710] After 6 h of treatment, compound 3 inhibited the expression of β-catenin in a concentration-dependent manner (IC 50 The compound inhibited FynB-induced Tau (Y18)-phosphorylation at 0.131 μM. After 24 hours of treatment, the compound still maintained its inhibitory activity, with an average inhibition percentage of 95% at 1 μM concentration. A moderate but non-significant effect on the total amount of Tau protein was observed.
[0711] Example 60: Inhibition of VEGF-induced VEGFR (Y1175)-phosphorylation (cell-based assay)
[0712] HUVEC-C cells (human umbilical vein endothelial cells from ATCC) were cultured in 24 w microplates at 6 × 10 4 Cells / well were plated and grown in medium F12K+0.1mg / ml heparin+0.05mg / ml ECGS+10% FBS at 5% CO2 and 37°C. After 24 hours, the medium was removed and starvation was induced overnight in medium F12K+0.1mg / ml heparin+0.5% FBS (moderate starvation). At the end of the incubation, the cells were cultured by replacing the medium and adding diluent (final concentration of 0.1% DMSO) or test compounds (range 10 -8 M-10 -5 M) were used for cell treatment. After 1 hour, VEGF stimulant (final concentration of 50 ng / ml) was added to each sample, except for the "basal amount-no stimulation" sample; the plate was then incubated for 5 min at 5% CO2 and 37°C. At the end of the incubation, the medium was removed and cell lysates were obtained by adding M-PER cleavage / protease / phosphatase inhibitor cocktail. The lysate was then transferred to an Eppendorf tube, sonicated, and stored at -80°C.
[0713] Lysates were analyzed by Western blot to determine VEGFR phosphorylation (tyrosine 1175) and total receptors. Sample lanes were densitometry analyzed using ImageQuant TL software (GE Healthcare Life Sciences). Each sample value was standardized by its respective actin; the resulting data were used to calculate the inhibitory effect of the compound relative to the stimulation control (in the absence of inhibitor).
[0714] result
[0715] Starting from a concentration of 0.01 μM, compound 3 exhibited complete inhibitory activity against VEGFR-phosphorylation at the Y1175 residue.
[0716] Example 61: Gene expression analysis of rat articular chondrocytes under inflammatory symptoms (IL-1β stimulation)
[0717] Rat primary articular chondrocytes were obtained from the lower and upper limbs of Sprague Dawley rats according to the protocol used by Berenbaum and colleagues (Berenbaum F, Thomas G, Poiraudeau S, Bereziat G, Corvol MT, Masliah J. Insulin-like growth factors counteract the effect of interleukin1beta on type II phospholipase A2 expression and arachidonic acid release by rabbit articular chondrocytes. FEBS Lett 1994; 340: 51-55). All studies involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals adopted and promulgated by the National Institutes of Health.
[0718] The purified chondrocytes were resuspended in 10% DMEM glutamine (glutaMAX) solution and placed in 96X well plates for toxicity analysis and in 6X well plates for gene expression analysis.
[0719] For toxicity analysis, cells were then treated with different compounds for 24 and 48 hours. At the end of the incubation time, the culture medium was removed and replaced with a 10% 10:1 DMEM glutamine-MTT (2 mg / ml) mixture for 1 h at 37°C in a cell culture incubator. After incubation, precipitated salts were dissolved with 100 μl DMSO and the plates were read at 540 nm. Toxicity analysis was performed to determine the maximum non-toxic concentration of each compound used in the gene expression analysis.
[0720] For gene expression analysis, after 10 days of incubation, the medium was changed and replaced with 0.4% DMEM Glutamine I to synchronize the cells. The cells were then co-treated with different concentrations of test compounds and IL-1β at a final concentration of 2 ng / ml in 0.4% DMEM Glutamine I for 6 h and 24 h. The concentrations of test compounds used have been selected based on toxicity data.
[0721] At the end of the incubation, the supernatant was discarded, the cells were washed with cold PBS 1X, and the cells were scraped with 200 μl RNA Lysis Buffer 1X (Nucleic Acid Purification Lysis Buffer, Applied Biosystems).
[0722] Total RNA was purified using the ABI Prism™ 6100 Nucleic Acid Sample Preparation Station (PrepStation) (Applied Biosystems) according to the manufacturer's instructions.
[0723] Total RNA was reverse transcribed using the High Capacity cDNA Library Kit (Applied Biosystems-Thermo Fisher Scientific) following the manufacturer's instructions.
[0724] Specific probes and primers for real-time PCR were purchased from Applied Biosystems (Thermo Fisher Scientific) under the trademark Assays-on-Demand TM , while the probe and primers for the endogenous control 18S were PDAR (previously developed Analytical Reagents - Applied Biosystems - Thermo Fisher Scientific).
[0725] Gene expression of the most relevant proinflammatory markers and matrix-degrading enzymes upregulated in osteoarthropathy was analyzed.
[0726] The assay is designed to amplify target cDNA and not genomic DNA.
[0727] At 6 h of incubation, gene expression analysis of IL-1β, IL-6, ADAMTS-5 was performed, and at 24 h of incubation, gene expression analysis of MMP3, MMP13, COX2 was performed. For each compound, the maximum concentration tested depended on the toxicity results obtained on primary rat chondrocytes.
[0728] Data analysis (normalization of 18S amplification values) was performed according to the Applied Biosystems specifications for relative quantification of gene expression.
[0729] Table 15: Gene expression analysis of the most relevant pro-inflammatory markers and matrix degradation markers induced after IL-1β stimulation (IC 50 μM or percentage of inhibition at the highest non-toxic concentration)
[0730]
[0731]
[0732] ne: no effect
[0733] result
[0734] As shown in Table 15, most of the compounds of the present invention were shown to inhibit the gene expression of the studied pro-inflammatory markers (IL-1β, IL-6, COX2) and degradation markers (ADAMTS-5, MMP3, MMP13), especially compound 3 inhibited the gene expression induced by IL-1β stimulation at submicromolar concentrations.
[0735] Example 62: Inhibition of cartilage degradation in a bovine in vitro model
[0736] Septal cartilage was collected from an 8-month-old male cow from a local slaughterhouse.
[0737] The tissue was sprayed with 70% ethanol and immediately placed in sterile PBS containing antibiotic-antimycotic stabilizing solution (PBS-AASS). It was cut to obtain small pieces (punches) (2 mm in diameter, 1 mm thick). Washed with sterile PBS-AASS, the slices were transferred to a 96X well plate (one slice per well) containing 10% DMEM+AASS. After 48 hours, the cartilage was stimulated in white DMEM+0.1% BSA+AASS containing 10 ng / ml IL-1α in the absence or presence of the studied compound.
[0738] The compound concentrations used in this assay were selected based on toxicity results obtained in rat primary chondrocytes at 48 h of incubation.
[0739] After 48 hours of stimulation, the culture medium was collected and stored at -80° C. The cartilage heads were digested with papain in phosphate buffer (0.05 M, pH 6,5, containing 2 mM N-acetyl-L-cysteine and 2 mM EDTA) at 65° C. for 2 h.
[0740] Glycosaminoglycans (GAGs) were determined by 1,9-dimethylmethylene blue (DMB) colorimetric method.
[0741] Dilute the digested cartilage samples in 1% PBS-BSA. Add 100 μl of DMB 2X to 100 μl of diluted samples or standards. After incubation for 5-20 min, read the samples at 590 nm (Titertek Multiscan Plus).
[0742] The expression of IL-1α-induced cartilage degradation is:
[0743] GAG (medium) / total GAG (medium + cartilage) x 100
[0744] Table 16: Inhibitory effect on IL-1α-induced bovine cartilage degradation
[0745]
[0746] ne: no effect
[0747] result
[0748] As shown in Table 16, most of the compounds of the present invention were shown to inhibit cartilage degradation induced by IL-1α, and in particular, compounds 3, 13, 15 and 34 were able to completely inhibit (inhibition between 95-100%) the release of GAGs.
[0749] Example 63: Description of the "in vivo" pharmacological activity of the compounds of the invention
[0750] The compounds of formula (I) have been shown to be potent analgesics in inflammatory, acute pain models. The analgesic efficacy of the compounds of formula (I) has been tested in the following in vivo animal models of inflammatory pain.
[0751] Complete Freund's adjuvant (CFA)-induced inflammatory pain in rats.
[0752] CFA was injected intradermally in the rat hind paw to induce inflammation and hyperalgesia that lasted for a long time. Compound 3 was injected into the right hind paw of male Wistar rats in the same bolus containing 50 μg of Mycobacterium tuberculosis dissolved in 100 μL of liquid paraffin (CFA). Eighteen hours after the challenge, the mechanical pain threshold was determined using the Randall-Selitto device, and the values obtained were compared with those obtained before the injection of CFA. The hyperalgesia assay was repeated 24, 42 and 48 hours after the injection of CFA.
[0753] result
[0754] Figure 1 and Figure 2 The results obtained for compound 3 in the CFA-induced inflammatory pain model are shown. The results demonstrate that compound 3 administered topically (intradermally, id) is a very potent inhibitor of CFA-induced hyperalgesia. The compound injected at a maximum concentration of 3 μM (i.e., 140 ng / paw) completely restored pain behavior in CFA-inflamed animals and did not alter normal nociception in naive animals that did not receive CFA challenge.
[0755] Example 64: Pharmacokinetics
[0756] Compound 3 is characterized by a suboptimal pharmacokinetic profile when administered by systemic routes. From the oral route, its absolute bioavailability is approximately 12% in mice and approximately 6% in rats. However, the lack of significant metabolism in rats and the associated local analgesic effects described make compound 3 particularly suitable for local treatment of OA by intra-articular injection.
[0757] Compound 3 was administered to rat knee joints as a suspension (150 mM phosphate buffer at pH 7, 0.5% HPMC, 0.1% Tween 80) and exhibited a depot-like long-term persistence in the synovial fluid and joint tissues (cartilage and synovial fat) for at least 14 days.
Claims
1. N-phenylcarbamoyl compound of formula (I) or its salt (I) in A is or in X is an optionally substituted group selected from the group consisting of a 6-membered heteroaryl ring, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, (6-membered heteroaryl)CO- and (phenyl)CO-; The 6-membered heteroaryl ring is selected from pyrazine, pyridine or pyrimidine, and the (6-membered heteroaryl)CO- is selected from (pyridine)CO- or (pyrimidine)CO-; Y is optionally substituted pyrazine; B is selected from the group consisting of optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl ring, optionally substituted pyrrolidine, unsubstituted azaspiro (C7-C 10 )alkyl and unsubstituted saturated (C3-C6)cycloalkyl-NH-; The 5- or 6-membered heteroaryl ring is selected from pyridine and oxazole, and the azaspiro (C7-C 10 ) alkyl is selected from azaspiro [3, 4] octane, azaspiro [4, 5] decane, and the saturated (C3-C6) cycloalkyl -NH- is selected from 4,4- (dimethylcyclohexyl) -NH-, cyclopentyl -NH-; R1 and R2 are optional and do not exist at the same time, and are independently selected from hydrogen, methyl, fluorine or chlorine; in, If the 6-membered heteroaryl ring is substituted, it is substituted with one or more substituents selected from the group consisting of: (C1-C3)alkyl, (morpholinyl)methyl, (dimethylmorpholinyl)methyl, pyrrolidin-1-yl-methyl, 4-ethylpiperazin-1-yl, 4-(2-hydroxyethyl)piperazin-1-yl, 3-hydroxyazetidin-1-yl, 3-(dimethylamino)pyrrolidin-1-yl, (2-hydroxyethyl)-1H-pyrazol-4-yl, morpholin-1-yl and cyano; If X is substituted 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl, it is substituted with one or more substituents selected from the group consisting of: (C1-C3)alkyl, hydroxy(C1-C3)alkyl, (C1-C3)alkylCO-; If X is substituted (phenyl)CO-, it is substituted with one or more substituents selected from the group consisting of halogen, (1-isopropylazetidin-3-yl)oxy, 4-methylpiperazin-1-yl and 1-methylpiperidin-4-yl; If B is substituted phenyl, it is selected from (C1-C3)alkyl, R'SO2-, R'R"N(C1-C3)alkyl, R'NH(C1-C3)alkyl, trifluoromethyl, difluoromethyl, halogen, R'R"NSO2-, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-NH-, NR'(C1-C3)alkyl, 3- C6) cycloalkyl-substituted with one or more substituents, wherein R' and R" are independently (C1-C3) alkyl; If B is a substituted 5- or 6-membered heteroaryl ring, it is substituted by one or more hydroxy(C1-C3)alkyl, CF3, fluorine, (C1-C4)alkyl, cyano(C1-C3)alkyl and (C3-C6)cycloalkyl-SO2-; If B is a substituted pyrrolidine, it is substituted with one or more (C1-C3)alkyl groups; If Y is a substituted pyrazine, it is substituted with one or more (C1-C3)alkyl groups.
2. The N-phenylcarbamoyl compound according to claim 1, wherein X is 2,3-dihydro-1H-pyrrolo[3,4-c]pyridinyl substituted with one or more substituents selected from the group consisting of ethyl, acetyl and 2-hydroxyethyl.
3. The N-phenylcarbamoyl compound according to claim 1, wherein the phenyl group is substituted with one or more substituents selected from the group consisting of CH3SO2-, -CH2N(CH3)2, CH3, CF3, CHF2, fluorine, -SO2N(CH3)2, and (N-ethyl)aminocyclopropyl.
4. The N-phenylcarbamoyl compound according to claim 1, wherein B is pyridine or oxazole, and the pyridine or oxazole is substituted with one or more substituents selected from the group consisting of 2-cyanopropyl-2-yl, 2-hydroxypropyl-2-yl, CH3, CF3, fluorine, isobutyl or cyclopropylsulfonyl. The N-phenylcarbamoyl compound according to claim 1 , wherein B is pyrrolidine.
6. The N-phenylcarbamoyl compound according to claim 1, wherein the pyrrolidine is substituted with one or more ethyl groups.
7. The N-phenylcarbamoyl compound according to claim 1, wherein A is .
8. The N-phenylcarbamoyl compound according to claim 7, wherein X is an optionally substituted 6-membered heteroaryl ring.
9. The N-phenylcarbamoyl compound according to claim 8, wherein X is an optionally substituted pyrazine.
10. The N-phenylcarbamoyl compound according to claim 7, wherein B is an optionally substituted phenyl group.
11. The N-phenylcarbamoyl compound according to claim 10, wherein the phenyl group is substituted by CF3.
12. The N-phenylcarbamoyl compound according to claim 1, which is selected from the group consisting of: 1) N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(methylsulfonyl)benzamide, 2) 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)isonicotinamide, 3) N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 4) 4-(1-(ethylamino)cyclopropyl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)benzamide, 5) 2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)isonicotinamide, 6) 2-methyl-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-5-(trifluoromethyl)oxazole-4-carboxamide, 7) 2-Fluoro-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-5-(trifluoromethyl)benzamide, 8) 4-(cyclopropylsulfonyl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)picolinamide, 9) N-(3-(2-fluoro-5-(6-isobutylnicotinamido)phenethyl)-1H-pyrazol-5-yl)pyrimidine-2-carboxamide, 10) N-(4-fluoro-3-(2-(5-((2-(2-hydroxyethyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 11) 2-(2-cyanopropan-2-yl)-N-(4-fluoro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)isonicotinamide, 12) N-(4-fluoro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(methylsulfonyl)benzamide, 13) N-(4-fluoro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 14) N-(3-(2-(5-((3,5-dimethylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-fluorophenyl)-3-(trifluoromethyl)benzamide, 15) N-(4-fluoro-3-(2-(5-((3-methylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 16) N-(4-chloro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 17) N-(3-(2-(5-((2-ethyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide, 18) N-(5-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenethyl)-1H-pyrazol-3-yl)picolinamide, 19) N-(3-(2-(3-(4-fluorobenzamido)-1H-pyrazol-5-yl)ethyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide, 20) N-(4-methyl-3-(2-(5-((3-methylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-6-azaspiro[3.4]octane-6-carboxamide, 21) 3,3-Diethyl-N-(4-methyl-3-(2-(5-((3-methylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)pyrrolidine-1-carboxamide 22) 3,3-Diethyl-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)pyrrolidine-1-carboxamide 23) N-(3-(5-(3-(4,4-dimethylcyclohexyl)ureido)-2-methylphenethyl)-1H-pyrazol-5-yl)-4-((1-isopropylazetidin-3-yl)oxy)benzamide, 24) N-(3-(5-(3-cyclopentylureido)-2-methylphenethyl)-1H-pyrazol-5-yl)-4-(4-methylpiperazin-1-yl)benzamide, 25) N-(3-(5-(3-(4,4-dimethylcyclohexyl)ureido)-2-methylphenethyl)-1H-pyrazol-5-yl)-4-(1-methylpiperidin-4-yl)benzamide, 26) N-(4-fluoro-3-(2-(3-((2-methyl-6-(morpholinomethyl)pyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 27) N-(3-(2-(3-((6-(((2S,6R)-2,6-dimethylmorpholinyl)methyl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)-4-fluorophenyl)-3-(trifluoromethyl)benzamide, 28) N-(4-fluoro-3-(2-(3-((2-methyl-6-(pyrrolidin-1-ylmethyl)pyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 29) N-(3-(2-(3-((6-(4-ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)-4-fluorophenyl)-3-(trifluoromethyl)benzamide, 30) N-(4-fluoro-3-(2-(3-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 31) N-(4-fluoro-3-(2-(3-((6-(3-hydroxyazetidin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 32) (S)-N-(3-(2-(3-((6-(3-(dimethylamino)pyrrolidin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)-4-fluorophenyl)-3-(trifluoromethyl)benzamide, 33) 3-(difluoromethyl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)benzamide, 34) N-(3-(2-(5-((2-acetyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide, 35) 3-(isopropylsulfonyl)-N-(4-methyl-3-(2-(5-((3-methylpyridin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)benzamide, 36) 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(5-((3-methylpyridin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)isonicotinamide, 37) N-(3-(2-(5-((6-cyano-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-3-(N,N-dimethylsulfamoyl)benzamide, 38) N-(3-(2-(5-((6-cyano-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-8-azaspiro[4.5]decane-8-carboxamide, 39) N-(3-(2-(5-((6-cyano-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-fluorophenyl)-4-((dimethylamino)methyl)-3-(trifluoromethyl)benzamide, 40) N-(4-fluoro-3-(2-(5-((2-methylpyrimidin-5-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 41) 4-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)picolinamide, 42) N-(4-fluoro-3-(2-(3-((6-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 43) N-(2-fluoro-5-(2-(5-((2-methyl-6-morpholinopyrimidin-4-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 44) N-(2-fluoro-5-(2-(3-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 45) N-(5-(2-(3-((6-(4-ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)-2-fluorophenyl)-3-(trifluoromethyl)benzamide, 46) N-(2-fluoro-5-(2-(3-((6-(3-hydroxyazetidin-1-yl)-2-methylpyrimidin-4-yl)amino)-1H-pyrazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 47) 4-((dimethylamino)methyl)-N-(3-(2-(5-(4-morpholinylbenzamido)-1H-pyrazol-3-yl)ethyl)phenyl)benzamide, 48) N-(4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)-3-(methylsulfonyl)benzamide, 49) N-(4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, and 50) 2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)isonicotinamide.
13. The N-phenylcarbamoyl compound according to claim 12, which is selected from the group consisting of: 3) N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 6) 2-methyl-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-5-(trifluoromethyl)oxazole-4-carboxamide, 8) 4-(cyclopropylsulfonyl)-N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)picolinamide, 13) N-(4-fluoro-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 15) N-(4-fluoro-3-(2-(5-((3-methylpyrazin-2-yl)amino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide, 34) N-(3-(2-(5-((2-acetyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)amino)-1H-pyrazol-3-yl)ethyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide, and 49) N-(4-methyl-3-(2-(2-(pyrazin-2-ylamino)thiazol-5-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide.
14. The N-phenylcarbamoyl compound according to claim 13, which is compound 3) N-(4-methyl-3-(2-(5-(pyrazin-2-ylamino)-1H-pyrazol-3-yl)ethyl)phenyl)-3-(trifluoromethyl)benzamide. 15 . A pharmaceutical composition comprising the N-phenylcarbamoyl compound (I) or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable excipient.
16. Use of an N-phenylcarbamoyl compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a medicament for inhibiting at least one tyrosine kinase selected from Fyn and VEGFR2 in the treatment of diseases and conditions associated with one or two kinases.
17. Use of an N-phenylcarbamoyl compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 16, wherein the use is to inhibit the kinases Fyn and VEGFR2 in the treatment of diseases / disorders / pathologies associated with both kinases.
18. The use of an N-phenylcarbamoyl compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 17, wherein the use is for treating a condition / disease / pathology, wherein the condition / disease / pathology is osteoarthritis, eye disease, skin disease, acute or chronic pain, lung disease, metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, recurrent glioblastoma multiforme, gynecological malignancies, metastatic breast cancer.
19. The use according to claim 18, wherein The eye disease is an intraocular neovascularization disorder.
20. The use according to claim 19, wherein The intraocular neovascularization disorder is age-related macular degeneration, diabetic macular edema and other ischemia-related retinopathies, or immune-mediated corneal transplant rejection.
21. The use according to claim 18, wherein The skin disorder is psoriasis or rosacea.
22. The use according to claim 18, wherein The acute or chronic pain is neuropathic pain, inflammatory pain, osteoarthritis pain, and eye pathology pain.
23. The use according to claim 18, wherein The lung disease is acute respiratory distress syndrome, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis or systemic sclerosis.
